US20120108613A1 - Compounds and compositions for treating chemical warfare agent-induced injuries - Google Patents
Compounds and compositions for treating chemical warfare agent-induced injuries Download PDFInfo
- Publication number
- US20120108613A1 US20120108613A1 US12/466,187 US46618709A US2012108613A1 US 20120108613 A1 US20120108613 A1 US 20120108613A1 US 46618709 A US46618709 A US 46618709A US 2012108613 A1 US2012108613 A1 US 2012108613A1
- Authority
- US
- United States
- Prior art keywords
- acetamide
- independently
- oxo
- alkyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 162
- 239000002575 chemical warfare agent Substances 0.000 title claims abstract description 36
- 230000006378 damage Effects 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 31
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 67
- 125000001072 heteroaryl group Chemical group 0.000 claims description 57
- 125000004122 cyclic group Chemical group 0.000 claims description 56
- -1 thioyl Chemical group 0.000 claims description 56
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 50
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 43
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 42
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 42
- 125000003368 amide group Chemical group 0.000 claims description 41
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 41
- 125000003282 alkyl amino group Chemical group 0.000 claims description 39
- 125000005843 halogen group Chemical group 0.000 claims description 39
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 32
- 229910020008 S(O) Inorganic materials 0.000 claims description 30
- 208000027418 Wounds and injury Diseases 0.000 claims description 29
- 208000014674 injury Diseases 0.000 claims description 29
- 229940100389 Sulfonylurea Drugs 0.000 claims description 28
- 125000004104 aryloxy group Chemical group 0.000 claims description 28
- 239000004202 carbamide Substances 0.000 claims description 28
- 125000005864 sulfonamidyl group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 18
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 15
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical group ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical group ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003491 tear gas Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 55
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 55
- 239000003795 chemical substances by application Substances 0.000 description 49
- 230000006870 function Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 20
- 108090000862 Ion Channels Proteins 0.000 description 17
- 102000004310 Ion Channels Human genes 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- 0 [1*]N1C=CC2=C(C1=O)N(C*C[3*])C=N2 Chemical compound [1*]N1C=CC2=C(C1=O)N(C*C[3*])C=N2 0.000 description 16
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 13
- 230000004907 flux Effects 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 229910001424 calcium ion Inorganic materials 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 102000003566 TRPV1 Human genes 0.000 description 10
- 101150016206 Trpv1 gene Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 235000003351 Brassica cretica Nutrition 0.000 description 9
- 235000003343 Brassica rupestris Nutrition 0.000 description 9
- 229940123524 TRPA1 antagonist Drugs 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 235000010460 mustard Nutrition 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241000219198 Brassica Species 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 102000003568 TRPV3 Human genes 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 101150043371 Trpv3 gene Proteins 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical group 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 108010036769 TRPA1 Cation Channel Proteins 0.000 description 6
- 102000012253 TRPA1 Cation Channel Human genes 0.000 description 6
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001299 aldehydes Chemical group 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091005462 Cation channels Proteins 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 102000003610 TRPM8 Human genes 0.000 description 5
- 101150111302 Trpm8 gene Proteins 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002576 ketones Chemical group 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 4
- 230000009460 calcium influx Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- GEAMNWUGWBCFOT-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 GEAMNWUGWBCFOT-UHFFFAOYSA-N 0.000 description 4
- GWVQMXGJOJVVAV-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 GWVQMXGJOJVVAV-UHFFFAOYSA-N 0.000 description 4
- BGDFLURCQCKHJL-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=2N=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 BGDFLURCQCKHJL-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960003456 pralidoxime chloride Drugs 0.000 description 4
- HIGSLXSBYYMVKI-UHFFFAOYSA-N pralidoxime chloride Chemical compound [Cl-].C[N+]1=CC=CC=C1\C=N\O HIGSLXSBYYMVKI-UHFFFAOYSA-N 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 3
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 3
- OBULTFWYQCCHDH-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 OBULTFWYQCCHDH-UHFFFAOYSA-N 0.000 description 3
- MUDCPEIZFAKWKH-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2C=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 MUDCPEIZFAKWKH-UHFFFAOYSA-N 0.000 description 3
- ASEMFLYDADTGFX-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C(C)=CC(=O)N2C)=C2N=C1 ASEMFLYDADTGFX-UHFFFAOYSA-N 0.000 description 3
- QIOCGGLZVXQFEA-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 QIOCGGLZVXQFEA-UHFFFAOYSA-N 0.000 description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- 102000003678 AMPA Receptors Human genes 0.000 description 3
- 108090000078 AMPA Receptors Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 101150092793 Trpa1 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- BSCOYGIDBGKPIX-UHFFFAOYSA-N diazenylphosphonic acid Chemical group OP(O)(=O)N=N BSCOYGIDBGKPIX-UHFFFAOYSA-N 0.000 description 3
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GIKLTQKNOXNBNY-OWOJBTEDSA-N lewisite Chemical class Cl\C=C\[As](Cl)Cl GIKLTQKNOXNBNY-OWOJBTEDSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010291 membrane polarization Effects 0.000 description 3
- QHOODWFRUQOFLR-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 QHOODWFRUQOFLR-UHFFFAOYSA-N 0.000 description 3
- IGWAOGPWHPQUTR-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 IGWAOGPWHPQUTR-UHFFFAOYSA-N 0.000 description 3
- WVZMQIVLCFIVDM-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 WVZMQIVLCFIVDM-UHFFFAOYSA-N 0.000 description 3
- JYFUHVMGCSGAPC-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 JYFUHVMGCSGAPC-UHFFFAOYSA-N 0.000 description 3
- AUBKPGBIZSSCBH-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 AUBKPGBIZSSCBH-UHFFFAOYSA-N 0.000 description 3
- RCMMHLMQMKZWMK-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 RCMMHLMQMKZWMK-UHFFFAOYSA-N 0.000 description 3
- LCCQDEUJXBQAGK-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 LCCQDEUJXBQAGK-UHFFFAOYSA-N 0.000 description 3
- OCOHGAGOBYWTMZ-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 OCOHGAGOBYWTMZ-UHFFFAOYSA-N 0.000 description 3
- XVXKTPNKGQVHHD-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 XVXKTPNKGQVHHD-UHFFFAOYSA-N 0.000 description 3
- OCJPPDPXQKUNSJ-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=C(Cl)C(OC)=CC2=C1OC(NC(=O)CN1C=3C(=O)C(C)N(C)C=3N=C1)=N2 OCJPPDPXQKUNSJ-UHFFFAOYSA-N 0.000 description 3
- FWUTZTGPENSITR-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 FWUTZTGPENSITR-UHFFFAOYSA-N 0.000 description 3
- DKYKXRMIADWYCI-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 DKYKXRMIADWYCI-UHFFFAOYSA-N 0.000 description 3
- TYQMTGIEMZJQHU-UHFFFAOYSA-N n-(6-fluoro-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 TYQMTGIEMZJQHU-UHFFFAOYSA-N 0.000 description 3
- SAXYWJDSDFGFKU-UHFFFAOYSA-N n-(6-fluoro-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 SAXYWJDSDFGFKU-UHFFFAOYSA-N 0.000 description 3
- KDZFHDSRSUFFOP-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 KDZFHDSRSUFFOP-UHFFFAOYSA-N 0.000 description 3
- YPULAPCHTAYZCR-UHFFFAOYSA-N n-(6-methoxy-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 YPULAPCHTAYZCR-UHFFFAOYSA-N 0.000 description 3
- ZZFDGUYWPAUHQW-UHFFFAOYSA-N n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound CC(=O)NCCC1=CC=C(C)C=C1 ZZFDGUYWPAUHQW-UHFFFAOYSA-N 0.000 description 3
- ZAZUYIZALIKTQU-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=2C=NC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 ZAZUYIZALIKTQU-UHFFFAOYSA-N 0.000 description 3
- AJGWTFCBCUMVKW-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=NC=2C(C)=CN(C)C(=O)C=2N1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 AJGWTFCBCUMVKW-UHFFFAOYSA-N 0.000 description 3
- IZPXJHDKXSBQKV-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 IZPXJHDKXSBQKV-UHFFFAOYSA-N 0.000 description 3
- QHROWCXWOJALFS-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=2C(=O)N(C)C=NC=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 QHROWCXWOJALFS-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- BVOMRRWJQOJMPA-UHFFFAOYSA-N 1,2,3-trithiane Chemical compound C1CSSSC1 BVOMRRWJQOJMPA-UHFFFAOYSA-N 0.000 description 2
- AMGNHZVUZWILSB-UHFFFAOYSA-N 1,2-bis(2-chloroethylsulfanyl)ethane Chemical compound ClCCSCCSCCCl AMGNHZVUZWILSB-UHFFFAOYSA-N 0.000 description 2
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- VMOFQFUWSNCZSA-UHFFFAOYSA-N 2-(1-methyl-6-oxopurin-7-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(=O)N(C)C=N2)=C2N=C1 VMOFQFUWSNCZSA-UHFFFAOYSA-N 0.000 description 2
- VWJTTWVIJWHGHK-UHFFFAOYSA-N 2-(1-methyl-6-oxopurin-7-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=N2)=C2N=C1 VWJTTWVIJWHGHK-UHFFFAOYSA-N 0.000 description 2
- ZPNOFOYPYTTZJQ-UHFFFAOYSA-N 2-(1-methyl-6-oxopurin-7-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C=NC=3N=C2)=N1 ZPNOFOYPYTTZJQ-UHFFFAOYSA-N 0.000 description 2
- DAWGFLKEXHEEEQ-UHFFFAOYSA-N 2-(3-methyl-2-oxopurin-7-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C=NC(=O)N2C)=C2N=C1 DAWGFLKEXHEEEQ-UHFFFAOYSA-N 0.000 description 2
- GYPVZTIVXNKGMV-UHFFFAOYSA-N 2-(3-methyl-2-oxopurin-7-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C=NC(=O)N2C)=C2N=C1 GYPVZTIVXNKGMV-UHFFFAOYSA-N 0.000 description 2
- SRRLVHUYLCVIPZ-UHFFFAOYSA-N 2-(3-methyl-2-oxopurin-7-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C=NC(=O)N(C)C=3N=C2)=N1 SRRLVHUYLCVIPZ-UHFFFAOYSA-N 0.000 description 2
- OUKXNNQHARQNAX-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(=O)C(C)N2C)=C2N=C1 OUKXNNQHARQNAX-UHFFFAOYSA-N 0.000 description 2
- DTLMASKANCYKPE-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 DTLMASKANCYKPE-UHFFFAOYSA-N 0.000 description 2
- UOMPHRUJSDRPDN-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C(OC)=CC2=C1SC(NC(=O)CN1C=3C(=O)C(C)N(C)C=3N=C1)=N2 UOMPHRUJSDRPDN-UHFFFAOYSA-N 0.000 description 2
- RYLPUNVSPPOPFR-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C(OC)=CC2=C1OC(NC(=O)CN1C=3C(=O)C(C)N(C)C=3N=C1)=N2 RYLPUNVSPPOPFR-UHFFFAOYSA-N 0.000 description 2
- ZOMPUZLPBJRACD-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)CN1C(C(=O)C(C)N2C)=C2N=C1 ZOMPUZLPBJRACD-UHFFFAOYSA-N 0.000 description 2
- DAJSKYZTFIKECE-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound O1C2=CC(OC)=CC=C2N=C1NC(=O)CN1C(C(=O)C(C)N2C)=C2N=C1 DAJSKYZTFIKECE-UHFFFAOYSA-N 0.000 description 2
- KXHXXQIDTSGFQT-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(=O)C(C)N2C)=C2N=C1 KXHXXQIDTSGFQT-UHFFFAOYSA-N 0.000 description 2
- ANEOATSEYGLRKN-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(=O)C(C)N2C)=C2N=C1 ANEOATSEYGLRKN-UHFFFAOYSA-N 0.000 description 2
- PUQAULSZVIKICZ-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NCCC1=CC=C(C)C=C1 PUQAULSZVIKICZ-UHFFFAOYSA-N 0.000 description 2
- OVQJIGBYXFXLLZ-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(C)C(C)=C1 OVQJIGBYXFXLLZ-UHFFFAOYSA-N 0.000 description 2
- URXQBDYPFFKOQU-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 URXQBDYPFFKOQU-UHFFFAOYSA-N 0.000 description 2
- FMJOCNJGVJGHBM-UHFFFAOYSA-N 2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(C)C=C1 FMJOCNJGVJGHBM-UHFFFAOYSA-N 0.000 description 2
- UIUPTCURKJDKCL-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2C=N1 UIUPTCURKJDKCL-UHFFFAOYSA-N 0.000 description 2
- PFQVIXBKADNXHN-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 PFQVIXBKADNXHN-UHFFFAOYSA-N 0.000 description 2
- MHBIYDQFLBCUJZ-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 MHBIYDQFLBCUJZ-UHFFFAOYSA-N 0.000 description 2
- YGBUOUYBVJPPQO-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 YGBUOUYBVJPPQO-UHFFFAOYSA-N 0.000 description 2
- CXEQITKPVZJRRO-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 CXEQITKPVZJRRO-UHFFFAOYSA-N 0.000 description 2
- WLQYUHMHPRTUQT-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 WLQYUHMHPRTUQT-UHFFFAOYSA-N 0.000 description 2
- WYIZJLLTZAEZCX-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 WYIZJLLTZAEZCX-UHFFFAOYSA-N 0.000 description 2
- MMFXNKCMMNZUAO-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2C=N1 MMFXNKCMMNZUAO-UHFFFAOYSA-N 0.000 description 2
- CHELWYWWDZLTQZ-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2C=N1 CHELWYWWDZLTQZ-UHFFFAOYSA-N 0.000 description 2
- WAMXWQSOTDEDSV-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C(=O)N(C)C=3C=N2)=N1 WAMXWQSOTDEDSV-UHFFFAOYSA-N 0.000 description 2
- PPRKVRGPFRXFEZ-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C(=O)N(C)C=3C=N2)=N1 PPRKVRGPFRXFEZ-UHFFFAOYSA-N 0.000 description 2
- XAXZJHVAQJXAJC-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2N=N1 XAXZJHVAQJXAJC-UHFFFAOYSA-N 0.000 description 2
- RZMZXGDHDLHLPW-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 RZMZXGDHDLHLPW-UHFFFAOYSA-N 0.000 description 2
- QGNVZKHGBMFIQK-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 QGNVZKHGBMFIQK-UHFFFAOYSA-N 0.000 description 2
- VQGQABCHVXRDAI-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 VQGQABCHVXRDAI-UHFFFAOYSA-N 0.000 description 2
- CVOJEUZNKOORPQ-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 CVOJEUZNKOORPQ-UHFFFAOYSA-N 0.000 description 2
- LIXSJPPEVAKFRU-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 LIXSJPPEVAKFRU-UHFFFAOYSA-N 0.000 description 2
- OFNMNNGPENIDLP-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 OFNMNNGPENIDLP-UHFFFAOYSA-N 0.000 description 2
- OXVMFGDIUSBBAX-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2N=N1 OXVMFGDIUSBBAX-UHFFFAOYSA-N 0.000 description 2
- QYCKHDGMDSZPJU-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2N=N1 QYCKHDGMDSZPJU-UHFFFAOYSA-N 0.000 description 2
- UZNWZVVZJSQWPN-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C(=O)N2C)=C2N=N1 UZNWZVVZJSQWPN-UHFFFAOYSA-N 0.000 description 2
- BJIRZPVSCFIHBA-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C(=O)N(C)C=3N=N2)=N1 BJIRZPVSCFIHBA-UHFFFAOYSA-N 0.000 description 2
- UQGGWFGZQCJBMC-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 UQGGWFGZQCJBMC-UHFFFAOYSA-N 0.000 description 2
- ZMNWWCNHBJJUSK-UHFFFAOYSA-N 2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C(=O)N(C)C=3N=N2)=N1 ZMNWWCNHBJJUSK-UHFFFAOYSA-N 0.000 description 2
- UNSOHBPJICWUAA-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(C)=CC(=O)N2C)=C2N=C1 UNSOHBPJICWUAA-UHFFFAOYSA-N 0.000 description 2
- PJRLULKKARMCSF-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 PJRLULKKARMCSF-UHFFFAOYSA-N 0.000 description 2
- YVEGNOQVVHQREL-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 YVEGNOQVVHQREL-UHFFFAOYSA-N 0.000 description 2
- CFOXDFUDKHCEMN-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)C=C(C)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 CFOXDFUDKHCEMN-UHFFFAOYSA-N 0.000 description 2
- HVHPELQUDSSHRZ-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)C=C(C)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 HVHPELQUDSSHRZ-UHFFFAOYSA-N 0.000 description 2
- VWVLMAKFUKTIPW-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)C=C(C)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 VWVLMAKFUKTIPW-UHFFFAOYSA-N 0.000 description 2
- DANSVOZHSIEXJA-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)C=C(C)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 DANSVOZHSIEXJA-UHFFFAOYSA-N 0.000 description 2
- XYNDRCASGUGIDU-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(C)=CC(=O)N2C)=C2N=C1 XYNDRCASGUGIDU-UHFFFAOYSA-N 0.000 description 2
- GETJZOAFLGZMEU-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(C)=CC(=O)N2C)=C2N=C1 GETJZOAFLGZMEU-UHFFFAOYSA-N 0.000 description 2
- RYBMHCFVCAJEBS-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(C)=CC(=O)N(C)C=3N=C2)=N1 RYBMHCFVCAJEBS-UHFFFAOYSA-N 0.000 description 2
- IJNDUEZSMGRORT-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(C)=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 IJNDUEZSMGRORT-UHFFFAOYSA-N 0.000 description 2
- PYXKQNBEHOSHNM-UHFFFAOYSA-N 2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(C)=CC(=O)N(C)C=3N=C2)=N1 PYXKQNBEHOSHNM-UHFFFAOYSA-N 0.000 description 2
- AZVVXGHOSAZUMD-UHFFFAOYSA-N 2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(N=CC(=O)N2C)=C2N=C1 AZVVXGHOSAZUMD-UHFFFAOYSA-N 0.000 description 2
- XPXVTJREKKITHO-UHFFFAOYSA-N 2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3N=CC(=O)N(C)C=3N=C2)=N1 XPXVTJREKKITHO-UHFFFAOYSA-N 0.000 description 2
- VZJILNHVVCQNDK-UHFFFAOYSA-N 2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C=CC(=O)N2C)=C2N=C1 VZJILNHVVCQNDK-UHFFFAOYSA-N 0.000 description 2
- RWTYKLRCYDQCID-UHFFFAOYSA-N 2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C=CC(=O)N2C)=C2N=C1 RWTYKLRCYDQCID-UHFFFAOYSA-N 0.000 description 2
- QCGRQORGYKEGDL-UHFFFAOYSA-N 2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C=CC(=O)N(C)C=3N=C2)=N1 QCGRQORGYKEGDL-UHFFFAOYSA-N 0.000 description 2
- KWCFNJHGNIMLOV-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CC1=NNC2=C1C(=O)N(C)C(=O)N2C KWCFNJHGNIMLOV-UHFFFAOYSA-N 0.000 description 2
- AYWIISKLOFHTDP-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 AYWIISKLOFHTDP-UHFFFAOYSA-N 0.000 description 2
- DBLULTOLBKYTCR-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 DBLULTOLBKYTCR-UHFFFAOYSA-N 0.000 description 2
- KNZGYLJLNWFJBC-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 KNZGYLJLNWFJBC-UHFFFAOYSA-N 0.000 description 2
- DJPRIUQROYMFRQ-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 DJPRIUQROYMFRQ-UHFFFAOYSA-N 0.000 description 2
- OGLXIVXAQRBKBX-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 OGLXIVXAQRBKBX-UHFFFAOYSA-N 0.000 description 2
- PNEPNARYHGLHPV-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CC1=NNC2=C1C(=O)N(C)C(=O)N2C PNEPNARYHGLHPV-UHFFFAOYSA-N 0.000 description 2
- JGXHLPFHTNZDAB-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CC1=NNC2=C1C(=O)N(C)C(=O)N2C JGXHLPFHTNZDAB-UHFFFAOYSA-N 0.000 description 2
- FJCUABYUYFEBRN-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CC=2C=3C(=O)N(C)C(=O)N(C)C=3NN=2)=N1 FJCUABYUYFEBRN-UHFFFAOYSA-N 0.000 description 2
- MVEOHKVRYVEQNM-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2NN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 MVEOHKVRYVEQNM-UHFFFAOYSA-N 0.000 description 2
- QJDGLWPIKPMXPB-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CC=2C=3C(=O)N(C)C(=O)N(C)C=3NN=2)=N1 QJDGLWPIKPMXPB-UHFFFAOYSA-N 0.000 description 2
- UBVFYWGKTHKSBL-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(4-propan-2-ylphenyl)acetamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)CN1C(C(=O)N(C)C=C2C)=C2N=C1 UBVFYWGKTHKSBL-UHFFFAOYSA-N 0.000 description 2
- OLSJPOFDMYLGNC-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-fluoro-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 OLSJPOFDMYLGNC-UHFFFAOYSA-N 0.000 description 2
- VWJIFQVBFCWGSY-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-fluoro-1,3-benzoxazol-2-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 VWJIFQVBFCWGSY-UHFFFAOYSA-N 0.000 description 2
- AGOZTTMQUAITSI-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 AGOZTTMQUAITSI-UHFFFAOYSA-N 0.000 description 2
- LGUACIQZLXQTHY-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 LGUACIQZLXQTHY-UHFFFAOYSA-N 0.000 description 2
- LPGYKPSZFBGHIH-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-methoxy-1,3-benzothiazol-2-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 LPGYKPSZFBGHIH-UHFFFAOYSA-N 0.000 description 2
- PPDNUKRQDYNXPE-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-(6-methoxy-1,3-benzoxazol-2-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 PPDNUKRQDYNXPE-UHFFFAOYSA-N 0.000 description 2
- DFYXIMYNZZFBDY-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[2-(4-ethylphenyl)ethyl]acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=C2C)=C2N=C1 DFYXIMYNZZFBDY-UHFFFAOYSA-N 0.000 description 2
- CESRUVBPOVCCCL-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[2-(4-methoxyphenyl)ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=C2C)=C2N=C1 CESRUVBPOVCCCL-UHFFFAOYSA-N 0.000 description 2
- RPHDQLQMXLEFRH-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=C2C)=C2N=C1 RPHDQLQMXLEFRH-UHFFFAOYSA-N 0.000 description 2
- ACPMQNFXBGMAQV-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C=C(C)C=3N=C2)=N1 ACPMQNFXBGMAQV-UHFFFAOYSA-N 0.000 description 2
- SRBWHCXXFUBFMC-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=NC=2C(C)=CN(C)C(=O)C=2N1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 SRBWHCXXFUBFMC-UHFFFAOYSA-N 0.000 description 2
- YNPRPBWWQVOYMD-UHFFFAOYSA-N 2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[4-(4-methylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C=C(C)C=3N=C2)=N1 YNPRPBWWQVOYMD-UHFFFAOYSA-N 0.000 description 2
- YOTONIHNFJJTGV-UHFFFAOYSA-N 2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)-n-[5-(4-methylphenyl)-3h-pyrrol-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CCC(NC(=O)CN2C=3C(=O)N(C)C=CC=3N=C2)=N1 YOTONIHNFJJTGV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 2
- UQZPGHOJMQTOHB-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)-n-ethylethanamine Chemical compound ClCCN(CC)CCCl UQZPGHOJMQTOHB-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VNLWSRCNEZBXGN-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C(F)=C2)O1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C(F)=C2)O1 VNLWSRCNEZBXGN-UHFFFAOYSA-N 0.000 description 2
- IMOONGFXXJYTNW-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C(=O)N(C)C=N3)=N2 Chemical compound COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C(=O)N(C)C=N3)=N2 IMOONGFXXJYTNW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 2
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000003565 TRPV2 Human genes 0.000 description 2
- 102000003567 TRPV4 Human genes 0.000 description 2
- 101150098315 TRPV4 gene Proteins 0.000 description 2
- 102000003570 TRPV5 Human genes 0.000 description 2
- 102000003569 TRPV6 Human genes 0.000 description 2
- 101150096736 TRPV6 gene Proteins 0.000 description 2
- 101150077905 Trpv2 gene Proteins 0.000 description 2
- 101150034091 Trpv5 gene Proteins 0.000 description 2
- 102000037089 Uniporters Human genes 0.000 description 2
- 108091006293 Uniporters Proteins 0.000 description 2
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 2
- 102100033024 Voltage-dependent T-type calcium channel subunit alpha-1G Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 125000003828 azulenyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- XUHFBOUSHUEAQZ-UHFFFAOYSA-N bromobenzyl cyanide Chemical compound N#CC(Br)C1=CC=CC=C1 XUHFBOUSHUEAQZ-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YRFJGLQNTWLXKO-ZPUQHVIOSA-N chloro-bis[(e)-2-chloroethenyl]arsane Chemical compound Cl\C=C\[As](Cl)\C=C\Cl YRFJGLQNTWLXKO-ZPUQHVIOSA-N 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- BDHNJKLLVSRGDK-UHFFFAOYSA-N diphenylcyanoarsine Chemical compound C=1C=CC=CC=1[As](C#N)C1=CC=CC=C1 BDHNJKLLVSRGDK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VXRMBBLRHSRVDK-UHFFFAOYSA-N methyldichloroarsine Chemical compound C[As](Cl)Cl VXRMBBLRHSRVDK-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- VXZHMLBPKIYBBV-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 VXZHMLBPKIYBBV-UHFFFAOYSA-N 0.000 description 2
- QXAFBLSWLGRUCS-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 QXAFBLSWLGRUCS-UHFFFAOYSA-N 0.000 description 2
- JKUZQSLFYJGMCR-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 JKUZQSLFYJGMCR-UHFFFAOYSA-N 0.000 description 2
- XLEHPLMTIBYTRR-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 XLEHPLMTIBYTRR-UHFFFAOYSA-N 0.000 description 2
- YKWBSTWWQRLEBC-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 YKWBSTWWQRLEBC-UHFFFAOYSA-N 0.000 description 2
- CBVDUZRTXGDXDQ-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 CBVDUZRTXGDXDQ-UHFFFAOYSA-N 0.000 description 2
- SGEFMMMFGJSCHS-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 SGEFMMMFGJSCHS-UHFFFAOYSA-N 0.000 description 2
- YGBOOAJFKUATKP-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 YGBOOAJFKUATKP-UHFFFAOYSA-N 0.000 description 2
- KSQFDDLQWAOLCG-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 KSQFDDLQWAOLCG-UHFFFAOYSA-N 0.000 description 2
- UWBRYEUXEOSAJJ-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 UWBRYEUXEOSAJJ-UHFFFAOYSA-N 0.000 description 2
- UZGOXNPLQOMRRO-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 UZGOXNPLQOMRRO-UHFFFAOYSA-N 0.000 description 2
- ZBUWXTXRFYFHCV-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 ZBUWXTXRFYFHCV-UHFFFAOYSA-N 0.000 description 2
- REWKCCOSLISOPY-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 REWKCCOSLISOPY-UHFFFAOYSA-N 0.000 description 2
- MTZWDCCUCZIXIU-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 MTZWDCCUCZIXIU-UHFFFAOYSA-N 0.000 description 2
- MZHSVWPLWARZPF-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 MZHSVWPLWARZPF-UHFFFAOYSA-N 0.000 description 2
- ARDARTZYMUQABV-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 ARDARTZYMUQABV-UHFFFAOYSA-N 0.000 description 2
- QDQSEJWKXBOFME-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound ClC1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 QDQSEJWKXBOFME-UHFFFAOYSA-N 0.000 description 2
- HYWPEJOKRVFDTB-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 HYWPEJOKRVFDTB-UHFFFAOYSA-N 0.000 description 2
- OHVPVYCOSZXLFR-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 OHVPVYCOSZXLFR-UHFFFAOYSA-N 0.000 description 2
- ASFKLOCHULJSND-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 ASFKLOCHULJSND-UHFFFAOYSA-N 0.000 description 2
- RTJZKRKWTTUUIZ-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 RTJZKRKWTTUUIZ-UHFFFAOYSA-N 0.000 description 2
- BOAZDBJSRCDLHO-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 BOAZDBJSRCDLHO-UHFFFAOYSA-N 0.000 description 2
- HSZZLJCGDYXNEB-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 HSZZLJCGDYXNEB-UHFFFAOYSA-N 0.000 description 2
- TVTDHIKIBWDRJM-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 TVTDHIKIBWDRJM-UHFFFAOYSA-N 0.000 description 2
- LGBSHFMOWQKESJ-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound FC1=C(F)C=C2SC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 LGBSHFMOWQKESJ-UHFFFAOYSA-N 0.000 description 2
- NQLDJHKIUJLEHA-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 NQLDJHKIUJLEHA-UHFFFAOYSA-N 0.000 description 2
- PBVOXJXFKZNSQV-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 PBVOXJXFKZNSQV-UHFFFAOYSA-N 0.000 description 2
- VXQGPYRJGGPLAD-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 VXQGPYRJGGPLAD-UHFFFAOYSA-N 0.000 description 2
- OAGWELWZSSOYHL-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 OAGWELWZSSOYHL-UHFFFAOYSA-N 0.000 description 2
- GBJKOAZQVLANAB-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 GBJKOAZQVLANAB-UHFFFAOYSA-N 0.000 description 2
- IXPOGQSCSBSODV-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 IXPOGQSCSBSODV-UHFFFAOYSA-N 0.000 description 2
- ZDKNHAGCWPOOKF-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 ZDKNHAGCWPOOKF-UHFFFAOYSA-N 0.000 description 2
- SBERAWPVGTVQHS-UHFFFAOYSA-N n-(5,6-difluoro-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound FC1=C(F)C=C2OC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 SBERAWPVGTVQHS-UHFFFAOYSA-N 0.000 description 2
- ISOUFLRRYDFFDA-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 ISOUFLRRYDFFDA-UHFFFAOYSA-N 0.000 description 2
- YTHXLWPWRDOEHD-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 YTHXLWPWRDOEHD-UHFFFAOYSA-N 0.000 description 2
- YKFWFVDPXQBBAJ-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 YKFWFVDPXQBBAJ-UHFFFAOYSA-N 0.000 description 2
- KWENIFZXRWOJQA-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 KWENIFZXRWOJQA-UHFFFAOYSA-N 0.000 description 2
- JEJNDYICBPDGDR-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 JEJNDYICBPDGDR-UHFFFAOYSA-N 0.000 description 2
- SNRUADALQCJAPJ-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C(C=NC=43)=O)C)=NC2=C1 SNRUADALQCJAPJ-UHFFFAOYSA-N 0.000 description 2
- ZFBMCTNMDCSGKW-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 ZFBMCTNMDCSGKW-UHFFFAOYSA-N 0.000 description 2
- DTAZJVIWIIIZCS-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 DTAZJVIWIIIZCS-UHFFFAOYSA-N 0.000 description 2
- VBYWVUMITKRQEY-UHFFFAOYSA-N n-(6-chloro-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=C(Cl)C=C2OC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 VBYWVUMITKRQEY-UHFFFAOYSA-N 0.000 description 2
- PIBLAAFQHNOWKD-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=C(Cl)C(OC)=CC2=C1SC(NC(=O)CN1C=3C(=O)C(C)N(C)C=3N=C1)=N2 PIBLAAFQHNOWKD-UHFFFAOYSA-N 0.000 description 2
- VDKMVUVSOIUVTM-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 VDKMVUVSOIUVTM-UHFFFAOYSA-N 0.000 description 2
- CKNVASCCYMINSR-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 CKNVASCCYMINSR-UHFFFAOYSA-N 0.000 description 2
- OZKKYPJNJDTKMQ-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 OZKKYPJNJDTKMQ-UHFFFAOYSA-N 0.000 description 2
- OMMKFNLJCAQDPH-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound CN1C(=O)N=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 OMMKFNLJCAQDPH-UHFFFAOYSA-N 0.000 description 2
- JRFFWYAGIBZBIP-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1C=NN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 JRFFWYAGIBZBIP-UHFFFAOYSA-N 0.000 description 2
- JJKMWTMVUKCYCZ-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=NN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 JJKMWTMVUKCYCZ-UHFFFAOYSA-N 0.000 description 2
- SYXAQEVHXLYPMD-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=C(C)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 SYXAQEVHXLYPMD-UHFFFAOYSA-N 0.000 description 2
- SQPAFEZOXRZVPA-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1NN=C2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 SQPAFEZOXRZVPA-UHFFFAOYSA-N 0.000 description 2
- LGIGUIPSIFLAPT-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound CC1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 LGIGUIPSIFLAPT-UHFFFAOYSA-N 0.000 description 2
- WJMGLJHQFJYNNE-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 WJMGLJHQFJYNNE-UHFFFAOYSA-N 0.000 description 2
- BCUVNDZPRZYPKP-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 BCUVNDZPRZYPKP-UHFFFAOYSA-N 0.000 description 2
- HAUDVWSTSSKVMV-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=C(F)C=C2SC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 HAUDVWSTSSKVMV-UHFFFAOYSA-N 0.000 description 2
- ZEFKEIPDJICEJZ-UHFFFAOYSA-N n-(6-fluoro-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 ZEFKEIPDJICEJZ-UHFFFAOYSA-N 0.000 description 2
- UIWZJDRTLSKLFJ-UHFFFAOYSA-N n-(6-fluoro-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=C(F)C=C2OC(NC(=O)CN3C=NC=4C=CN(C(C=43)=O)C)=NC2=C1 UIWZJDRTLSKLFJ-UHFFFAOYSA-N 0.000 description 2
- CNGIRLHTOOQZLK-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound N1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 CNGIRLHTOOQZLK-UHFFFAOYSA-N 0.000 description 2
- IQSHXRXDUZOLJP-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound CN1C(=O)N=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 IQSHXRXDUZOLJP-UHFFFAOYSA-N 0.000 description 2
- QAKXDMKFBGFTAB-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound CN1C(=O)C=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 QAKXDMKFBGFTAB-UHFFFAOYSA-N 0.000 description 2
- GWCRPFWXKWYIHV-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2S1 GWCRPFWXKWYIHV-UHFFFAOYSA-N 0.000 description 2
- KFBJMYXQFRPKOU-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound N1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 KFBJMYXQFRPKOU-UHFFFAOYSA-N 0.000 description 2
- UPJDFTDYPPEOMQ-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound CN1C(=O)N=CC2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 UPJDFTDYPPEOMQ-UHFFFAOYSA-N 0.000 description 2
- VNQADIGNNTVMGI-UHFFFAOYSA-N n-(6-fluoro-5-methoxy-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)F)OC)=C2O1 VNQADIGNNTVMGI-UHFFFAOYSA-N 0.000 description 2
- DTUJHBYJRXCYIN-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound N1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 DTUJHBYJRXCYIN-UHFFFAOYSA-N 0.000 description 2
- RYNGZFWMCUDOSA-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound CN1C(=O)N=CC2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 RYNGZFWMCUDOSA-UHFFFAOYSA-N 0.000 description 2
- RLSFSRFEKSDSCU-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2S1 RLSFSRFEKSDSCU-UHFFFAOYSA-N 0.000 description 2
- MGYWQBBFCPCODB-UHFFFAOYSA-N n-(6-methoxy-1,3-benzoxazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound N1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 MGYWQBBFCPCODB-UHFFFAOYSA-N 0.000 description 2
- GXNZNPOBVVJBTE-UHFFFAOYSA-N n-(6-methoxy-1,3-benzoxazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound CN1C(=O)N=CC2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 GXNZNPOBVVJBTE-UHFFFAOYSA-N 0.000 description 2
- LEGVNEIRJRIRPX-UHFFFAOYSA-N n-(6-methoxy-1,3-benzoxazol-2-yl)-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=CN(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC2=CC=C(OC)C=C2O1 LEGVNEIRJRIRPX-UHFFFAOYSA-N 0.000 description 2
- FUNGEYOVULUFCG-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N=CN(C(C=43)=O)C)=NC2=C1 FUNGEYOVULUFCG-UHFFFAOYSA-N 0.000 description 2
- CXHOTNSCSBIULM-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N(C(N=CC=43)=O)C)=NC2=C1 CXHOTNSCSBIULM-UHFFFAOYSA-N 0.000 description 2
- CKNBUAVDQAQMGJ-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N(C)C(C(C=43)=O)C)=NC2=C1 CKNBUAVDQAQMGJ-UHFFFAOYSA-N 0.000 description 2
- WMIBUFNVDAOYPB-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3N=CC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 WMIBUFNVDAOYPB-UHFFFAOYSA-N 0.000 description 2
- FYSRDCGNICPVFV-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3N=NC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 FYSRDCGNICPVFV-UHFFFAOYSA-N 0.000 description 2
- JERGMLZOYIUAKD-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N(C)C(=O)C=C(C3=4)C)=NC2=C1 JERGMLZOYIUAKD-UHFFFAOYSA-N 0.000 description 2
- USNGHQSSWHHYFI-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N(C(C=NC=43)=O)C)=NC2=C1 USNGHQSSWHHYFI-UHFFFAOYSA-N 0.000 description 2
- LQYZSNRRNPIXRH-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=NC=4N(C(C=CC=43)=O)C)=NC2=C1 LQYZSNRRNPIXRH-UHFFFAOYSA-N 0.000 description 2
- AEIBFOQLQQMOBS-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CC3=NNC=4N(C(N(C)C(=O)C=43)=O)C)=NC2=C1 AEIBFOQLQQMOBS-UHFFFAOYSA-N 0.000 description 2
- YKALLTLOCZTLCS-UHFFFAOYSA-N n-(6-tert-butyl-1,3-benzothiazol-2-yl)-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C2SC(NC(=O)CN3C=4C(=O)N(C)C=C(C=4N=C3)C)=NC2=C1 YKALLTLOCZTLCS-UHFFFAOYSA-N 0.000 description 2
- UHNVANOVFOJJCP-UHFFFAOYSA-N n-[2-(4-ethylphenyl)ethyl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=N2)=C2N=C1 UHNVANOVFOJJCP-UHFFFAOYSA-N 0.000 description 2
- PEMMDUZJOAQFJN-UHFFFAOYSA-N n-[2-(4-ethylphenyl)ethyl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C=NC(=O)N2C)=C2N=C1 PEMMDUZJOAQFJN-UHFFFAOYSA-N 0.000 description 2
- NSJKCSCRLQLNHG-UHFFFAOYSA-N n-[2-(4-ethylphenyl)ethyl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(N=CC(=O)N2C)=C2N=C1 NSJKCSCRLQLNHG-UHFFFAOYSA-N 0.000 description 2
- LJODTPADYVYDGJ-UHFFFAOYSA-N n-[2-(4-ethylphenyl)ethyl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)CN1C(C=CC(=O)N2C)=C2N=C1 LJODTPADYVYDGJ-UHFFFAOYSA-N 0.000 description 2
- MAEYJQWDTBUHOY-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C(=O)N(C)C=N2)=C2N=C1 MAEYJQWDTBUHOY-UHFFFAOYSA-N 0.000 description 2
- VNGQESIQFGGXRD-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C=NC(=O)N2C)=C2N=C1 VNGQESIQFGGXRD-UHFFFAOYSA-N 0.000 description 2
- UFTZPMHKBMQMPH-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(N=CC(=O)N2C)=C2N=C1 UFTZPMHKBMQMPH-UHFFFAOYSA-N 0.000 description 2
- XXPYQMRSNNTNIR-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)CN1C(C=CC(=O)N2C)=C2N=C1 XXPYQMRSNNTNIR-UHFFFAOYSA-N 0.000 description 2
- ICINHDPHYJJMLX-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=2C(=O)N(C)C=NC=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 ICINHDPHYJJMLX-UHFFFAOYSA-N 0.000 description 2
- WFJJRNLOSFAJFX-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 WFJJRNLOSFAJFX-UHFFFAOYSA-N 0.000 description 2
- XYENRCPNMCALPO-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2C=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 XYENRCPNMCALPO-UHFFFAOYSA-N 0.000 description 2
- FSVFMDWTUWLTOT-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 FSVFMDWTUWLTOT-UHFFFAOYSA-N 0.000 description 2
- JHBPEWUSIVVBGN-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 JHBPEWUSIVVBGN-UHFFFAOYSA-N 0.000 description 2
- GMBRVCGTALMQPN-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2NN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 GMBRVCGTALMQPN-UHFFFAOYSA-N 0.000 description 2
- CAZHJJHMWWRGNX-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C=CC=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 CAZHJJHMWWRGNX-UHFFFAOYSA-N 0.000 description 2
- GSEYHZQSXSEYBH-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=2C=NC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 GSEYHZQSXSEYBH-UHFFFAOYSA-N 0.000 description 2
- CRLUTCPZXNVCIR-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 CRLUTCPZXNVCIR-UHFFFAOYSA-N 0.000 description 2
- SDVYQULMGYUARR-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2C=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 SDVYQULMGYUARR-UHFFFAOYSA-N 0.000 description 2
- BSCBUICCQUOVMR-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C(C)=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 BSCBUICCQUOVMR-UHFFFAOYSA-N 0.000 description 2
- HIKYOCIHXATNLU-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=2N=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 HIKYOCIHXATNLU-UHFFFAOYSA-N 0.000 description 2
- OWRXSVNTEPHJBG-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 OWRXSVNTEPHJBG-UHFFFAOYSA-N 0.000 description 2
- JUIHGVASWQUBFO-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2NN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 JUIHGVASWQUBFO-UHFFFAOYSA-N 0.000 description 2
- QUBQUZSQFBSPPK-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=NC=2C(C)=CN(C)C(=O)C=2N1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 QUBQUZSQFBSPPK-UHFFFAOYSA-N 0.000 description 2
- RSXLCZVGOMKQEP-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C=CC=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 RSXLCZVGOMKQEP-UHFFFAOYSA-N 0.000 description 2
- LADUTXVMDXTEKI-UHFFFAOYSA-N n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C=NC(=O)N(C)C=3N=C2)=N1 LADUTXVMDXTEKI-UHFFFAOYSA-N 0.000 description 2
- OJGZBDARTOIZJM-UHFFFAOYSA-N n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3N=CC(=O)N(C)C=3N=C2)=N1 OJGZBDARTOIZJM-UHFFFAOYSA-N 0.000 description 2
- DOVNCYDEQNXGNU-UHFFFAOYSA-N n-[4-(3,4-dimethylphenyl)-1,3-thiazol-2-yl]-2-(5-methyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=C(C)C(C)=CC=C1C1=CSC(NC(=O)CN2C=3C(=O)N(C)C=CC=3N=C2)=N1 DOVNCYDEQNXGNU-UHFFFAOYSA-N 0.000 description 2
- DWTSHELQGRIORQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(3-methyl-2-oxopurin-7-yl)acetamide Chemical compound C1=2C=NC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 DWTSHELQGRIORQ-UHFFFAOYSA-N 0.000 description 2
- FGSIWEXMLCEYQG-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 FGSIWEXMLCEYQG-UHFFFAOYSA-N 0.000 description 2
- OECWMZSKRBVIHV-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2C=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 OECWMZSKRBVIHV-UHFFFAOYSA-N 0.000 description 2
- HNYIREXCMDZOKQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxotriazolo[4,5-d]pyrimidin-1-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=NN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 HNYIREXCMDZOKQ-UHFFFAOYSA-N 0.000 description 2
- CHSXDOJQKNUEDW-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4,7-dimethyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C(C)=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 CHSXDOJQKNUEDW-UHFFFAOYSA-N 0.000 description 2
- WYIPWXBYRDZKRS-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyrazin-1-yl)acetamide Chemical compound C1=2N=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 WYIPWXBYRDZKRS-UHFFFAOYSA-N 0.000 description 2
- YPJMODIAVHARRY-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 YPJMODIAVHARRY-UHFFFAOYSA-N 0.000 description 2
- QHQSBPBEHSQCKV-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-2h-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2NN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 QHQSBPBEHSQCKV-UHFFFAOYSA-N 0.000 description 2
- OGTSVIVNEIEJHH-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4-oxoimidazo[4,5-c]pyridin-3-yl)acetamide Chemical compound C1=NC=2C(C)=CN(C)C(=O)C=2N1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 OGTSVIVNEIEJHH-UHFFFAOYSA-N 0.000 description 2
- DFWFGXNJBLHVHY-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=2C(=O)N(C)C=NC=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 DFWFGXNJBLHVHY-UHFFFAOYSA-N 0.000 description 2
- UMBFYBPAYFLMBD-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-(4-methyl-5-oxoimidazo[4,5-b]pyridin-1-yl)acetamide Chemical compound C1=2C=CC(=O)N(C)C=2N=CN1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1 UMBFYBPAYFLMBD-UHFFFAOYSA-N 0.000 description 2
- SQAYOHTWOQIQLO-UHFFFAOYSA-N n-[5-(3,4-difluorophenyl)-3h-pyrrol-2-yl]-2-(1-methyl-6-oxopurin-7-yl)acetamide Chemical compound C1=2C(=O)N(C)C=NC=2N=CN1CC(=O)NC(CC=1)=NC=1C1=CC=C(F)C(F)=C1 SQAYOHTWOQIQLO-UHFFFAOYSA-N 0.000 description 2
- AXSIBBMUBNPTFV-YCRREMRBSA-N n-[5-[(e)-2,3-dichloroprop-1-enyl]-1,3-thiazol-2-yl]-2-(4,5-dimethyl-6-oxo-5h-pyrrolo[2,3-d]imidazol-1-yl)acetamide Chemical compound C1=2C(=O)C(C)N(C)C=2N=CN1CC(=O)NC1=NC=C(\C=C(\Cl)CCl)S1 AXSIBBMUBNPTFV-YCRREMRBSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- UDHDFEGCOJAVRE-UHFFFAOYSA-N phenyldichloroarsine Chemical compound Cl[As](Cl)C1=CC=CC=C1 UDHDFEGCOJAVRE-UHFFFAOYSA-N 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 2
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 2
- AOAVIJUEFJPSAI-GZDDRBCLSA-N tris[(e)-2-chloroethenyl]arsane Chemical compound Cl\C=C\[As](\C=C\Cl)\C=C\Cl AOAVIJUEFJPSAI-GZDDRBCLSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- YHRGRBPJIRKFND-UHFFFAOYSA-N 1,3-bis(2-chloroethylsulfanyl)propane Chemical compound ClCCSCCCSCCCl YHRGRBPJIRKFND-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- AQJNKLADFCYHNW-UHFFFAOYSA-N 1,3-dichloro-1-(1,3-dichloropropylsulfanyl)propane Chemical compound ClCCC(Cl)SC(Cl)CCCl AQJNKLADFCYHNW-UHFFFAOYSA-N 0.000 description 1
- AYSIRJGVBLMLAS-UHFFFAOYSA-N 1,4-bis(2-chloroethylsulfanyl)butane Chemical compound ClCCSCCCCSCCCl AYSIRJGVBLMLAS-UHFFFAOYSA-N 0.000 description 1
- CUJOZMZOOCTTAZ-UHFFFAOYSA-N 1,5-bis(2-chloroethylsulfanyl)pentane Chemical compound ClCCSCCCCCSCCCl CUJOZMZOOCTTAZ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- FWVCSXWHVOOTFJ-UHFFFAOYSA-N 1-(2-chloroethylsulfanyl)-2-[2-(2-chloroethylsulfanyl)ethoxy]ethane Chemical compound ClCCSCCOCCSCCCl FWVCSXWHVOOTFJ-UHFFFAOYSA-N 0.000 description 1
- CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 1
- IJGBNRTYNRKNHS-UHFFFAOYSA-N 1-chloro-2-(2-chloroethylsulfanylmethoxymethylsulfanyl)ethane Chemical compound ClCCSCOCSCCCl IJGBNRTYNRKNHS-UHFFFAOYSA-N 0.000 description 1
- RKTJTTAEKCRXNL-UHFFFAOYSA-N 1-chloro-2-(2-chloroethylsulfanylmethylsulfanyl)ethane Chemical compound ClCCSCSCCCl RKTJTTAEKCRXNL-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- QXISTPDUYKNPLU-UHFFFAOYSA-N 2-bromo-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(Br)=C1 QXISTPDUYKNPLU-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HGMITUYOCPPQLE-UHFFFAOYSA-N 3-quinuclidinyl benzilate Chemical compound C1N(CC2)CCC2C1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HGMITUYOCPPQLE-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 102000021944 Butyrylcholinesterase Human genes 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- MGTAHTDCIZPLGQ-UHFFFAOYSA-N CC(C)C1=CC=C(NC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 Chemical compound CC(C)C1=CC=C(NC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 MGTAHTDCIZPLGQ-UHFFFAOYSA-N 0.000 description 1
- RKUVCLSSMXZLFK-UHFFFAOYSA-N CC1=CC(=O)N(C)C2=C1N(CC(=O)NC1=NC(C3=CC=C(Cl)C(Cl)=C3)=CS1)C=N2 Chemical compound CC1=CC(=O)N(C)C2=C1N(CC(=O)NC1=NC(C3=CC=C(Cl)C(Cl)=C3)=CS1)C=N2 RKUVCLSSMXZLFK-UHFFFAOYSA-N 0.000 description 1
- HQKXXBDBTVOOMP-UHFFFAOYSA-N CC1=CC=C(C2=CSC(NC(=O)CN3C=NC4=C3C(=O)N(C)C=N4)=N2)C=C1C Chemical compound CC1=CC=C(C2=CSC(NC(=O)CN3C=NC4=C3C(=O)N(C)C=N4)=N2)C=C1C HQKXXBDBTVOOMP-UHFFFAOYSA-N 0.000 description 1
- IJMYRQFSEUKQPR-UHFFFAOYSA-N CC1=CC=C(C2=CSC(NC(=O)CN3C=NC4=C3C=CC(=O)N4C)=N2)C=C1C Chemical compound CC1=CC=C(C2=CSC(NC(=O)CN3C=NC4=C3C=CC(=O)N4C)=N2)C=C1C IJMYRQFSEUKQPR-UHFFFAOYSA-N 0.000 description 1
- XSSYCXAEMWWKDS-UHFFFAOYSA-N CC1=CC=C(CCNC(=O)CC2=NNC3=C2C(=O)N(C)C(=O)N3C)C=C1 Chemical compound CC1=CC=C(CCNC(=O)CC2=NNC3=C2C(=O)N(C)C(=O)N3C)C=C1 XSSYCXAEMWWKDS-UHFFFAOYSA-N 0.000 description 1
- JDXSKWPLYPAEOY-UHFFFAOYSA-N CC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 Chemical compound CC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 JDXSKWPLYPAEOY-UHFFFAOYSA-N 0.000 description 1
- ZEBSZJATIPPOTM-UHFFFAOYSA-N CC1=CC=C(CCNC(=O)CN2C=NC3=C2N=CC(=O)N3C)C=C1 Chemical compound CC1=CC=C(CCNC(=O)CN2C=NC3=C2N=CC(=O)N3C)C=C1 ZEBSZJATIPPOTM-UHFFFAOYSA-N 0.000 description 1
- XWPCCZYABWOHOL-UHFFFAOYSA-N CC1=CC=C(CCNC(=O)CN2N=CC3=C2C(=O)N(C)C(=O)N3C)C=C1 Chemical compound CC1=CC=C(CCNC(=O)CN2N=CC3=C2C(=O)N(C)C(=O)N3C)C=C1 XWPCCZYABWOHOL-UHFFFAOYSA-N 0.000 description 1
- JMBLRWAUPKYFPN-UHFFFAOYSA-N CCC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 Chemical compound CCC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 JMBLRWAUPKYFPN-UHFFFAOYSA-N 0.000 description 1
- OYTGUYZNPFDAND-UHFFFAOYSA-N CN1C(=O)C2=C(N=NN2CC(=O)NC2=NC3=C(C=C(Cl)C=C3)O2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=NN2CC(=O)NC2=NC3=C(C=C(Cl)C=C3)O2)N(C)C1=O OYTGUYZNPFDAND-UHFFFAOYSA-N 0.000 description 1
- MTCFMLBQODGSPR-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC(C2=CC=C(Cl)C(Cl)=C2)=CS1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC(C2=CC=C(Cl)C(Cl)=C2)=CS1 MTCFMLBQODGSPR-UHFFFAOYSA-N 0.000 description 1
- FBNWNYKGHUPOHT-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(Cl)C(Cl)=C2)O1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(Cl)C(Cl)=C2)O1 FBNWNYKGHUPOHT-UHFFFAOYSA-N 0.000 description 1
- XCBLXDAAHBCNBZ-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(Cl)C(Cl)=C2)S1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(Cl)C(Cl)=C2)S1 XCBLXDAAHBCNBZ-UHFFFAOYSA-N 0.000 description 1
- NFDGZSMWGCQTFF-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C(F)=C2)S1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C(F)=C2)S1 NFDGZSMWGCQTFF-UHFFFAOYSA-N 0.000 description 1
- QLSJKLSQSVGMQT-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C=C2)O1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C=C2)O1 QLSJKLSQSVGMQT-UHFFFAOYSA-N 0.000 description 1
- UOBCMEZQNNFUCI-UHFFFAOYSA-N CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C=C2)S1 Chemical compound CN1C(=O)C=NC2=C1N=CN2CC(=O)NC1=NC2=C(C=C(F)C=C2)S1 UOBCMEZQNNFUCI-UHFFFAOYSA-N 0.000 description 1
- JWOXSFJIAKRNLU-UHFFFAOYSA-N CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC(C3=CC=C(Cl)C=C3)=CS1)C=N2 Chemical compound CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC(C3=CC=C(Cl)C=C3)=CS1)C=N2 JWOXSFJIAKRNLU-UHFFFAOYSA-N 0.000 description 1
- ULABMRRCOANXGN-UHFFFAOYSA-N CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC(C3=CC=C(F)C=C3)=CS1)C=N2 Chemical compound CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC(C3=CC=C(F)C=C3)=CS1)C=N2 ULABMRRCOANXGN-UHFFFAOYSA-N 0.000 description 1
- BKDWCNHRESHSGB-UHFFFAOYSA-N CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC3=C(C=C(C(C)(C)C)C=C3)S1)C=N2 Chemical compound CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC3=C(C=C(C(C)(C)C)C=C3)S1)C=N2 BKDWCNHRESHSGB-UHFFFAOYSA-N 0.000 description 1
- ALSJVAJYODYJPL-UHFFFAOYSA-N CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC3=C(C=C(Cl)C=C3)O1)C=N2 Chemical compound CN1C=CC2=C(C1=O)N(CC(=O)NC1=NC3=C(C=C(Cl)C=C3)O1)C=N2 ALSJVAJYODYJPL-UHFFFAOYSA-N 0.000 description 1
- UGNCIJLJVVKMRI-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)O2 Chemical compound COC1=CC2=C(C=C1)N=C(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)O2 UGNCIJLJVVKMRI-UHFFFAOYSA-N 0.000 description 1
- FZPMOQXSIPPTEZ-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)S2 Chemical compound COC1=CC2=C(C=C1)N=C(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)S2 FZPMOQXSIPPTEZ-UHFFFAOYSA-N 0.000 description 1
- RKVKDMDEKRLOFF-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)OC(NC(=O)CN1C=NC3=C1C(=O)N(C)C=N3)=N2 Chemical compound COC1=CC2=C(C=C1Cl)OC(NC(=O)CN1C=NC3=C1C(=O)N(C)C=N3)=N2 RKVKDMDEKRLOFF-UHFFFAOYSA-N 0.000 description 1
- IBSLCRWCCGUXNM-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)OC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1Cl)OC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 IBSLCRWCCGUXNM-UHFFFAOYSA-N 0.000 description 1
- CEMAKLLCMZTEMR-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C(C)=CC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C(C)=CC(=O)N3C)=N2 CEMAKLLCMZTEMR-UHFFFAOYSA-N 0.000 description 1
- YCMNPUVVDADWMA-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C=NC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1C=NC(=O)N3C)=N2 YCMNPUVVDADWMA-UHFFFAOYSA-N 0.000 description 1
- ANRHXSZZTGPEAD-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1Cl)SC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 ANRHXSZZTGPEAD-UHFFFAOYSA-N 0.000 description 1
- AYECXXCKSCMVDU-UHFFFAOYSA-N COC1=CC2=C(C=C1F)OC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1F)OC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 AYECXXCKSCMVDU-UHFFFAOYSA-N 0.000 description 1
- ZWDQGTAMNUKEBX-UHFFFAOYSA-N COC1=CC2=C(C=C1F)SC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 Chemical compound COC1=CC2=C(C=C1F)SC(NC(=O)CN1C=NC3=C1N=CC(=O)N3C)=N2 ZWDQGTAMNUKEBX-UHFFFAOYSA-N 0.000 description 1
- AFMADKCNASLDGW-UHFFFAOYSA-N COC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 Chemical compound COC1=CC=C(CCNC(=O)CN2C=NC3=C2C(=O)N(C)C=C3)C=C1 AFMADKCNASLDGW-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical group S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 102000003623 TRPC6 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- PBNSPNYJYOYWTA-UHFFFAOYSA-N adamsite Chemical compound C1=CC=C2[As](Cl)C3=CC=CC=C3NC2=C1 PBNSPNYJYOYWTA-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000005021 aminoalkenyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005014 aminoalkynyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- RVSGRNKUJJUAPV-UHFFFAOYSA-N benzo[d][1,2]benzoxazepine Chemical compound O1N=CC2=CC=CC=C2C2=CC=CC=C12 RVSGRNKUJJUAPV-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- LFHISGNCFUNFFM-UHFFFAOYSA-N chloropicrin Chemical compound [O-][N+](=O)C(Cl)(Cl)Cl LFHISGNCFUNFFM-UHFFFAOYSA-N 0.000 description 1
- KNVLCWQKYHCADB-UHFFFAOYSA-N chlorosulfonyloxymethane Chemical compound COS(Cl)(=O)=O KNVLCWQKYHCADB-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- SNTRKUOVAPUGAY-UHFFFAOYSA-N cyclosarin Chemical compound CP(F)(=O)OC1CCCCC1 SNTRKUOVAPUGAY-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LQSFEOMOHFPNEB-UHFFFAOYSA-N dichloro(ethyl)arsane Chemical compound CC[As](Cl)Cl LQSFEOMOHFPNEB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- YHHKGKCOLGRKKB-UHFFFAOYSA-N diphenylchlorarsine Chemical compound C=1C=CC=CC=1[As](Cl)C1=CC=CC=C1 YHHKGKCOLGRKKB-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MFFXVVHUKRKXCI-UHFFFAOYSA-N ethyl iodoacetate Chemical compound CCOC(=O)CI MFFXVVHUKRKXCI-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- RTEJRWNKBLZSGX-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzothiazol-2-yl)-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2S1 RTEJRWNKBLZSGX-UHFFFAOYSA-N 0.000 description 1
- YJIPZDVNIOUDMW-UHFFFAOYSA-N n-(6-chloro-5-methoxy-1,3-benzoxazol-2-yl)-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(=O)NC1=NC(C=C(C(=C2)Cl)OC)=C2O1 YJIPZDVNIOUDMW-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- JIRJHEXNDQBKRZ-UHFFFAOYSA-N phosgene oxime Chemical compound ON=C(Cl)Cl JIRJHEXNDQBKRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000002710 riot control agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention relates to compounds and compositions useful for treating injuries caused by chemical warfare and similar agents.
- ion channel proteins exist to mediate ion flux across cellular membranes.
- the proper expression and function of ion channel proteins is essential for the maintenance of cell function and intracellular communication. Numerous diseases and disorders are the result of misregulation of membrane potential or aberrant calcium handling. Given the central importance of ion channels in modulating membrane potential and ion flux in cells, identification of agents that can promote or inhibit particular ion channels are of great interest, both as research tools and as therapeutic agents.
- the present invention provides compounds and compositions for treating or preventing injuries resulting from chemical warfare agents by modulating the activity of the TRPA1 channel.
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (II) or a salt thereof
- R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- X is N or CR 2
- R 2 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5′ ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , C(O), O, S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkyla
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising
- R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- X is N or CR 2
- R 2 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5′ ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, C(O), S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkyla
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (IV) or a salt thereof
- R 1 and R 2 are each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, C(O), S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dial
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (V) or a salt thereof
- R 1 and R 2 are each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, C(O), S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dial
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising
- R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- R 2 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or cyclyl, each of which is optionally substituted with 1-4 R 5 ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, C(O), S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (VII) or a salt thereof
- R 1 and R 2 are each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, C(O), S, S(O), S(O) 2 , NR 6 , CH 2 , cyclyl, aryl, heterocyclyl, or heteroaryl;
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dial
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (IX) or a salt thereof
- R 1 and R 2 are each independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with 1-4 R 5 ;
- L is NR 6 SO 2 , SO 2 NR 6 , OC(O)NR 6 , NR 6 C(O)O, NR 6 C(O)NR 6 , NR 6 C(O), C(O)NR 6 , O, S, S(O), S(O) 2 , NR 6 , or CH 2
- R 3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R 7 ;
- each R 5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cycly
- the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (X) or a salt thereof
- W represents O or S
- R independently for each occurrence, represents H or lower alkyl
- R′ represents substituted or unsubstituted alkyl or substituted or unsubstituted aryl
- E represents carboxylic acid (CO 2 H), ester or amide
- Ar represents a substituted or unsubstituted aryl ring.
- Exemplary compounds of Formula X are described in WO 2007/073505.
- the invention features a method of treating a subject who has been exposed to a chemical warfare agent, the method comprising administering to a subject an effective amount of a compound of Formula (II), (III), (IV), (V), (VI), (VII), (IX) or (X), or a salt thereof.
- the treatment reduces the severity of injury resulting from the exposure to the chemical warfare agent.
- the compound is administered orally, via intramuscular injection, by topical ocular administration, topically, or by inhalation.
- the subject being treated is a human.
- acyl refers to a group represented by the general formula hydrocarbylC(O)—, preferably alkylC(O)—.
- acylamino refers to a moiety that can be represented by the general formula:
- R 9 is as defined below, and R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m-R8, where m and R8 are as defined herein.
- aliphatic group refers to a straight-chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, and an alkynyl group.
- alkenyl refers to an aliphatic group containing at least one double bond.
- alkoxyl or “alkoxy” as used herein refers to an alkyl group, as defined below, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- An “ether” is two hydrocarbons covalently linked by an oxygen.
- alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl(alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
- a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains), and more preferably 20 or fewer, and most preferably 10 or fewer.
- preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- alkynyl refers to an aliphatic group containing at least one triple bond.
- alkylthio refers to a hydrocarbyl group having a sulfur radical attached thereto.
- the “alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, or —S-alkynyl.
- Representative alkylthio groups include methylthio, ethylthio, and the like.
- amine and “amino” refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:
- R 9 , R 10 and R′ 10 each independently represent a hydrogen, an alkyl, an alkenyl, —(CH 2 ) m —R 8 , or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure;
- R 8 represents an aryl, a cycloalkyl, a cycloalkenyl, an alkoxy, a heterocycle or a polycycle; and
- m is zero or an integer in the range of 1 to 8.
- R 9 , R 10 are as defined above.
- aralkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
- aryl as used herein includes 5-, 6-, and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
- aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics.”
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, polycyclyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, —CF3, —CN, or the like.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- carrier or cyclyl refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
- carbonyl refers to moieties represented by the general formula:
- X is a bond or represents an oxygen or a sulfur
- R 11 represents a hydrogen, an alkyl, an alkenyl, —(CH 2 ) m —R 8 or a pharmaceutically acceptable counter-ion
- R′ 11 represents a hydrogen, an alkyl, an alkenyl or —(CH 2 ) m —R 8 , where m and R 8 are as defined above.
- X is an oxygen and R 11 or R′ 11 is not hydrogen
- the formula represents an “ester”.
- X is an oxygen
- R 11 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R 11 is a hydrogen, the formula represents a “carboxylic acid”.
- esters refers to a group —C(O)OR 9 wherein R 9 represents a hydrocarbyl group.
- halo and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
- heteroalkyl and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
- heterocyclyl or “heterocyclic group” refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles.
- heterocyclyl or “heterocyclic group” includes “heteroaryl” and “saturated or partially saturated heterocyclyl” structures.
- heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). Any ring atom can be substituted (e.g., by one or more substituents).
- saturated or partially saturated heterocyclyl refers to a non-aromatic cyclic structure that includes at least one heteroatom.
- Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine,
- the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , —CN, or the like.
- substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphin
- heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
- hydrocarbyl refers to a group that is bonded through a carbon atom that does not have a ⁇ O or ⁇ S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms.
- groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a ⁇ O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not.
- Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
- nitro means —NO2
- halogen designates —F, —Cl, —Br or —I
- sulfhydryl means —SH
- hydroxyl means —OH
- sulfonyl means —SO2-.
- polycyclyl or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings.
- Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
- substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl
- Exemplary monocyclic rings include furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, and trithiane.
- Exemplary bicyclic rings include indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indenyl, naphthalenyl, azulenyl, imidazopyridazionyl, pyrazolopyrimidinedionyl, or pyrrolopyrimidinedionyl moieties.
- Exemplary tricyclic rings include carbazole, acridine, phenazine, phenothiazine, phenoxazine, fluorine, and anthracene.
- protecting group means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
- protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively.
- the field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991).
- substituted refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
- Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic mo
- the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
- the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF 3 , —CN and the like.
- Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF 3 , —CN, and the like.
- Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.
- R41 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
- sulfoxido or “sulfinyl,” as used herein, refers to a moiety that can be represented by the general formula —S( ⁇ O)—R44, in which R44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
- thioester refers to a group —C(O)SR 9 or —SC(O)R 9 wherein R 9 represents a hydrocarbyl.
- each expression e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
- Exemplary monocyclic rings include furan, thiophene, pyrrole, pyrroline, pyrrolodine, oxazole, thiazole, imidazole, imidazoline, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, and trithiane.
- Exemplary bicyclic rings include indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indenyl, naphthalenyl, azulenyl, imidazopyridazionyl, pyrazolopyrimidinedionyl, or pyrrolopyrimidinedionyl moieties.
- Exemplary tricyclic rings include carbazole, acridine, phenazine, phenothiazine, phenoxazine, fluorine, and anthracene.
- TRPA1 inhibitors include inhibitors having any combination of the structural and/or functional properties disclosed herein.
- an “effective amount” of, e.g., a TRPA1 antagonist, with respect to the subject methods of treatment refers to an amount of the antagonist in a preparation which, when applied as part of a desired dosage regimen brings about a desired clinical or functional result.
- an effective amount of a TRPA1 antagonist for use in the methods of the present invention includes an amount of a TRPA1 antagonist effective to decrease one or more in vitro or in vivo functions of a TRPA1 channel.
- Exemplary functions include, but are not limited to, membrane polarization (e.g., an antagonist may promote hyperpolarization of a cell), ion flux, ion concentration in a cell, outward current, and inward current.
- an effective amount is an amount sufficient to inhibit a TRPA1-mediated current and/or the amount sufficient to inhibit TRPA1 mediated ion flux.
- preventing when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition or injury in a subject relative to a subject which does not receive the composition.
- a condition such as a local recurrence (e.g., pain)
- a disease such as cancer
- a syndrome complex such as heart failure or any other medical condition
- prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.
- Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population.
- Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
- prodrug is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention.
- a common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule.
- the prodrug is converted by an enzymatic activity in the host animal.
- Exemplary compounds are provided in Table 1-7.
- Compounds of Formula II include those shown in Table 1.
- Compounds of Formula IV include those shown in Table 3.
- Compounds of Formula V include those shown in Table 4.
- Compounds of Formula VI include those shown in Table 5.
- Compounds of Formula VII include those shown in Table 6.
- Compounds of Formula IX include those shown in Table 7.
- Certain compounds disclosed herein may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- the invention includes racemic mixtures, enantiomerically enriched mixtures, and substantially enantiomerically pure compounds.
- the composition can contain, e.g., more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, or more than 99% of a single enantiomer.
- enantiomeric excess or “% enantiomeric excess” of a composition can be calculated using the equation shown below.
- a composition contains 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, i.e., the R enantiomer.
- composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%.
- a particular enantiomer of a compound disclosed herein may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- diastereomeric salts may be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
- enantiomerically enriched mixtures and pure enantiomeric compounds can be prepared by using synthetic intermediates that are enantiomerically pure in combination with reactions that either leave the stereochemistry at a chiral center unchanged or result in its complete inversion.
- Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are well known in the art, and it is well within the ability of one of skill in the art to choose an appropriate method for a particular situation. See, generally, Furniss et al. (eds.), Vogel's Encyclopedia of Practical Organic Chemistry 5 th Ed., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and Heller, Acc. Chem. Res. 23: 128 (1990).
- the compounds described herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention. For example, deuterated compounds and compounds incorporated 13 C are intended to be encompassed within the scope of the invention.
- Certain compounds disclosed herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds disclosed herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- certain embodiments of the present compounds may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds disclosed herein. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- lactate lactate
- phosphate tosylate
- citrate maleate
- fumarate succinate
- tartrate naphthylate
- mesylate mesylate
- glucoheptonate lactobionate
- laurylsulphonate salts and the like See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19.
- the compounds disclosed herein may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic base addition salts of compounds disclosed herein. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
- Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (See, for example, Berge et al., supra).
- An antagonist of TRPA1 function may inhibit the outward current, the inward current, or both currents. Compounds that inhibit both currents may do so with the same or with differing IC 50 values. The inhibition of a particular current is measured by the ability to inhibit or reduce such current (e.g., inward and/or outward) in an in vitro or an in vivo assay. Compounds that inhibit any of the foregoing currents in an in vitro or in vivo assay are characterized as compounds that inhibit a function of TRPA1. Additionally or alternatively, a further exemplary function of TRPA1 that may be inhibited by the present compounds is ion flux mediated by TRPA1.
- a compound described herein can be chosen for a use described herein may be chosen because it inhibits a TRPA1 function with an IC 50 less than or equal to 10 uM, 5 uM, 1 uM, or less than or equal to 700, 600, 500, 400, 300, 250, 200, or 100 nM. In other embodiments, the compound described herein inhibits a TRPA1 function with an IC 50 less than or equal to 75 nM, less than or equal to 50 nM, or less than or equal to 25, 10, 5, or 1 nM.
- inhibition of TRPA1 function means that a function, for example a TRPA1 mediated current, is decreased by greater than 50% in the presence of an effective amount of a compound in comparison to in the absence of the compound or in comparison to an ineffective amount of a compound.
- the inhibition of a TRPA1 function means that a function, for example a TRPA1 mediated current or TRPA1 mediated ion flux, is decreased by at least 50%, 60%, 70%, 75%, 80%, 85%, or 90% in the presence of an effective amount of a compound in comparison to in the absence of the compound.
- the inhibition of a TRPA1 function means that a function, for example a TRPA1 mediated current, is decreased by at least 92%, 95%, 97%, 98%, 99%, or 100% in the presence of an effective amount of a compound in comparison to in the absence of the compound.
- a compound described herein e.g., a TRPA1 antagonist
- can be characterized by some level of activity versus other ion channels e.g., certain compounds are selective for inhibiting TRPA1 and other compounds exhibit a level of cross reactivity against one or more other ion channel.
- a compound described herein is characterized by its activity against another ion channel
- inhibition of a function or activity of the other ion channel is defined analogously to the way in which a function of a TRPA1 channel is defined.
- inhibiting the function of another ion channel means, for example, inhibiting ion flux mediated by that other ion channel or inhibiting the current mediated by that other ion channel.
- a compound described herein is chosen for use because it is more selective for one TRP isoform than others, e.g., 10-fold, and more preferably at least 20, 40, 50, 60, 70, 80, or at least 100- or 1000-fold more selective for TRPA1 over one or more of TRPC6, TRPV5, TRPV6, TRPM8, TRPV1, TRPV2, TRPV4, and/or TRPV3.
- the differential is smaller, e.g., it more strongly inhibits TRPA1 than TRPM8, TRPV1, TRPV2, TRPV3, and/or TRPV4, preferably at least twice, three times, five times, or ten times more strongly. Such comparisons may be made, for example, by comparing IC 50 values.
- a compound described herein is chosen for use because it is more selective for TRPA1 than for other non-TRP ion channels, e.g., 10-fold, and more preferably at least 20, 40, 50, 60, 70, 80, or at least 100- or 1000-fold more selective for TRPA1 over one or more of NaV1.2, Cav1.2, Cav3.1, HERG, and/or mitochondrial uniporter.
- the differential is smaller, e.g., it more strongly inhibits TRPA1 than NaV1.2, Cav1.2, Cav3.1, HERG, and/or mitochondrial uniporter, preferably at least twice, three times, five times, or ten times more strongly.
- the compound described herein inhibits TRPA1 with an IC 50 at least one order of magnitude more potent than its Ki for the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.
- AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- the compound described herein inhibits TRPA1 with an IC 50 at least two orders of magnitude, three orders of magnitude, or four orders of magnitude more potent than its Ki for the AMPA receptor.
- the compound described herein does not appreciably bind the AMPA receptor.
- the compound described herein inhibits TRPA1 with a particular IC 50 and, when administered at that concentration, the antagonist does not appreciably bind the AMPA receptor.
- a compound is chosen because it antagonizes the function of TRPA1 and the function of TRPM8, TRPV1 and/or TRPV3. Although such compounds selectively antagonize the function of more than one ion channel, the IC 50 values for the different ion channels need not be identical.
- the IC 50 values are measured in vitro using, for example, patch clamp analysis or standard measurements of calcium flux. Exemplary in vitro methods for calcium flux-based IC 50 estimation are described in Example 2. Methods used to obtain more definitive IC 50 measurements are described in Example 3. Alternatively, estimates of % inhibition of current or ion flux can also be calculated and used to assess efficacy of a compound as an inhibitor.
- TRP channels are one large family of non-selective cation channels that function to help regulate ion flux and membrane potential.
- Non-selective cation channels such as TRPA1 modulate the flux of calcium and sodium ions across cellular membranes. Sodium and calcium influx leads to depolarization of the cell. This increases the probability that voltage-gated ion channels will reach the threshold required for activation. As a result, activation of non-selective cation channels can increase electrical excitability and increase the frequency of voltage-dependent events. Voltage-dependent events include, but are not limited to, neuronal action potentials, cardiac action potentials, smooth muscle contraction, cardiac muscle contraction, and skeletal muscle contraction.
- Non-selective cation channels such as TRPA1
- Calcium influx caused by the activation of non-selective cation channels such as TRPA1 also alters the intracellular free calcium concentration.
- Calcium is a ubiquitous second messenger molecule within the cell, so alterations in intracellular calcium levels have profound effects on signal transduction and gene expression.
- activation of non-selective cation channels such as TRPA1 can lead to changes in gene expression and cellular phenotype.
- Gene expression events include, but are not limited to, production of mRNAs encoding cell surface receptors, ion channels, and kinases. These changes in gene expression can lead to hyperexcitability in that cell.
- Modulating the function of TRPA1 proteins provides a means of modulating calcium homeostasis, sodium homeostasis, membrane polarization, and/or intracellular calcium levels
- compounds that can modulate TRPA1 function are useful in many aspects, including, but not limited to, maintaining calcium homeostasis, modulating intracellular calcium levels, modulating membrane polarization, and treating or preventing diseases, disorders, or conditions associated with calcium and/or sodium homeostasis or dyshomeostasis.
- Bautista et al. have reported that TRPA1 mediates the inflammatory actions of agents such as acrolein, which causes the inflammatory and toxic actions of tear gas. (Bautista et al., Cell (2006) 124:1269-82.) Bessac et al. have shown that hypochlorite—the main mediator of chlorine irritancy—activates Ca 2+ influx and membrane currents in sensory neurons cultured from Trpa1 +/+ mice, while the influx of Ca 2+ was absent in neurons cultured from Trpa1 ⁇ / ⁇ mice. In addition, Bessac et al. compared the responses of Trpa1 +/+ mice and Trpa1 ⁇ / ⁇ mice to NaOCl exposure.
- Trpa1 +/+ mice showed much more respiratory depression than did the Trpa1 ⁇ / ⁇ mice.
- TRPA1 antagonists could be useful to treat or prevent the effects of chemical warfare agents including tear gas and chlorine.
- a subject may be exposed to a chemical warfare agent, e.g., by inhalation or by contact with the skin.
- a compound described herein e.g., a TRPA1 antagonist
- the compound described herein can be administered to a subject before, during, or following such exposure and is therefore administered within 24 hours, 18 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 10 minutes, 5 minutes, one minute, or thirty seconds before or after such exposure.
- the TRPA1 anta compound described herein gonist can be administered prophylactically, when exposure to an agent is anticipated. It can also be administered after exposure to the chemical warfare agent (e.g., before or after symptoms of injury present in a subject).
- Injuries resulting from the exposure to chemical warfare agents are known in the art and include any physical injuries, such as injuries to the skin, eyes, respiratory tract, musculo-skeletal system, circulatory system, gastrointestinal tract, central nervous system, peripheral nervous system, heart, liver, lungs, and kidneys.
- Exemplary symptoms or injuries resulting from the exposure to chemical warfare agents include inflammation, burn, itch, pain, rash, blisters, sweating, muscle twitching, nausea, vomiting, diarrhea, weakness, loss of consciousness, convulsions, muscular twitching, paralysis, secretions (from the mouth, nose, or lung for example), difficulty breathing, blurred vision, eye pain, lacrimation, red eyes, shortness of breath, coughing, phlegm production and narrowing of the airways, headaches, tremors, dizziness, numbness or tingling, anxiety, insomnia, depression, emotional instability, and even death.
- chemical warfare agent includes all of those agents classified as schedule 1, 2, and 3 agents under the Chemical Weapons Convention of 1993 and may be in liquid form, gas form, solid form, or combinations thereof.
- agents are described in further detail below and include, for example, nerve agents, blood agents, blister agents, pulmonary agents, incapacitating agents, and toxins.
- Other agents include methyl isocyanate, hexamethylene diisocyanate, 2,4-toluene-diisocyanate, and diphenylmethane-4,4-diisocyanate (MDI).
- Nerve agents Nerve agent poisoning typically leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles. These symptoms are reduced or prevented by the administration of the TRPA1 antagonists.
- Exemplary agents include G agents such as tabun (GA), sarin (GB), soman (GD), cyclosarin (GF), and GV; V agents such as VE, VG, VM, VX, and Novichok agents.
- a blood agent is a compound containing a cyanide group that prevents the body from utilizing oxygen. These agents exert their toxic effect at the cellular level by directly interrupting cellular respiration. Exemplary agents include cyanogen chloride, hydrogen cyanide, and hydrogen sulfide.
- Blister agents typically cause severe skin, eye and mucosal pain and irritation. These agents also have the ability to cause large, painful water blisters. Blister agents include, for example, lewisites, nitrogen mustard, sulfur mustard, ethyldichloroarsine (a lewisite analog; ED), methyldichloroarsine (MD), phenyldichloroarsine (PD), and phosgene oxime (CX).
- Lewisites include, for example, 2-Chlorovinyldichloroarsine (Lewisite 1), Bis(2-chlorovinyl)chloroarsine (Lewisite 2), and Tris(2-chlorovinyl)arsine (Lewisite 3).
- Exemplary nitrogen mustards are bis(2-chloroethyl)ethylamine (HN1), bis(2-chloroethyl)methylamine (HN2), and tris(2-chloroethyl)amine (HN3).
- Sulfur mustards include, for example, 1,2-Bis(2-chloroethylthio)ethane (Sesquimustard; Q), 1,3-Bis(2-chloroethylthio)-n-propane, 1,4-Bis(2-chloroethylthio)-n-butane, 1,5-Bis(2-chloroethylthio)-n-pentane, 2-Chloroethylchloromethylsulfide, bis(2-chloroethyl) sulfide (Mustard gas; HD), bis(2-chloroethylthio) methane, bis(2-chloroethylthiomethyl)ether, and bis(2-chloroethylthioethyl)ether (0 Mustard).
- a pulmonary agent is a chemical weapon agent designed to impede a subject's ability to breathe, resulting in suffocation.
- exemplary agents include adamsite (DM), acrolein, bis(chloromethyl)ether (BCME), chlorine (Cl 2 ), chloropicrin (PS), diphosgene (DP), methyl chlorosulfonate, phosgene (CG), and stannic chloride.
- Incapacitating agents Inapacitating agents. Incapacitating agents or riot-control agents typically produce temporary physiological or mental effects, or both, such that individuals who are exposed to them are incapable of concerted effort. Upon their exposure, lachrymatory agents (or lachrymators) for example, irritate the eyes to cause tearing, pain, and even temporary blindness.
- lachrymatory agents or lachrymators
- the most common lachrymatory agents are tear gas and pepper spray and include, for example, a-Chlorotoluene, benzyl bromide, bromoacetone (BA), bromobenzylcyanide (CA) bromomethyl ethyl ketone, capsaicin (OC), chloracetophenone (Tear gas; CN), chloromethyl chloroformate, dibenzoxazepine (CR), ethyl iodoacetate, ortho-chlorobenzylidene malononitrile (Super tear gas; CS), trichloromethyl chloroformate, and xylyl bromide.
- a-Chlorotoluene bromoacetone
- CA bromobenzylcyanide
- OC capsaicin
- chloracetophenone Tear gas
- CN chloromethyl chloroformate
- dibenzoxazepine CR
- ethyl iodoacetate
- incapacitating agents include, for example, 3-Quinuclidinyl benzilate (psychedelic; BZ), hydrocyanic acid (paralytic), diphenylchloroarsine (sternutatory; DA), diphenylcyanoarsine (DC), and KOLOKOL-1 (tranquilizer).
- exemplary toxins are abrin, ricin, and saxitoxin.
- a compound disclosed herein While it is possible for a compound disclosed herein to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation, where the compound is combined with one or more pharmaceutically acceptable excipients or carriers.
- the compounds disclosed herein may be formulated for administration in any convenient way for use in human or veterinary medicine.
- the compound included in the pharmaceutical preparation may be active itself, or may be a prodrug, e.g., capable of being converted to an active compound in a physiological setting.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Examples of pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) algin
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- Solid dosage forms can include one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol
- Liquid dosage forms can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions disclosed herein may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- the formulations disclosed herein can be delivered via a device.
- Exemplary devices include, but are not limited to, a catheter, wire, stent, or other intraluminal device. Further exemplary delivery devices also include a patch, bandage, mouthguard, or dental apparatus.
- Transdermal patches have the added advantage of providing controlled delivery of a compound disclosed herein to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- a device is a metered dose aerosol dispenser containing an aerosol pharmaceutical composition for pulmonary or nasal delivery comprising an agent that inhibits a TRPA1-mediated current with an IC 50 of 1 micromolar or less.
- an agent that inhibits a TRPA1-mediated current with an IC 50 of 1 micromolar or less can be a metered dose inhaler, a dry powder inhaler or an air-jet nebulizer.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- the compounds disclosed herein are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- the formulations can be administered topically, orally, transdermally, rectally, vaginally, parentally, intranasally, intrapulmonary, intraocularly, intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intracardiacly, intradermally, intraperitoneally, transtracheally, subcutaneously, subcuticularly, intraarticularly, subcapsularly, subarachnoidly, intraspinally, intrasternally or by inhalation.
- Particularly useful modes of administration include topical administration, intramuscular injection, inhalation, topical ocular administration (e.g., via eye drops), or oral administration.
- Another aspect of the invention provides a conjoint therapy wherein one or more other therapeutic agents are administered with a compound described herein (e.g., a TRPA1 modulator such as an antagonist).
- a compound described herein e.g., a TRPA1 modulator such as an antagonist.
- Such conjoint treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of the treatment.
- two or more compounds of the invention are conjointly administered.
- the two or more compounds may have a similar selectivity profile and functional activity, or the two or more compounds may have a different selectivity profile and functional activity.
- the two or more compounds may both be approximately 10, 100, or 1000 fold selective for antagonizing a function of TRPA1 over TRPV1, TRPV5, and TRPV6 (e.g., the two or more compounds have a similar selectivity profile), and further may inhibit a function of TRPA1 with a similar IC 50 (e.g., a similar functional activity).
- the one of the two or more compounds may selectively inhibit TRPA1 while the other of the two or more compounds inhibits both TRPA1 and TRPV1 (e.g., the two or more compounds have differing selectivity profiles).
- Administration of combinations of two or more compounds of the invention having similar or differing properties are contemplated.
- a compound of the invention is conjointly administered with one or more additional compounds that antagonize the function of a different channel.
- a compound of the invention may be conjointly administered with one or more compounds that antagonize TRPV1, TRPM8, and/or TRPV3.
- the compound(s) that antagonize TRPV1, TPRM8, or TRPV3 may be selective for TRPV1, TRPM8 or TRPV3 (e.g., inhibit TRPV1 or TRPV3 10, 100, or 1000 fold more strongly than TRPA1).
- the compound(s) that antagonize TRPV1 or TRPV3 may cross react with other TRP channels.
- a compound of the invention is conjointly administered with one or more additional agents or therapeutic regimens appropriate for the particular injury being treated.
- current treatments for injuries caused by exposure to nerve agents include treatment with atropine and Pralidoxime chloride (2-PAM).
- Injuries caused by exposure to cyanides are currently treated with.
- Scavengers such as human plasma-derived butyrylcholinesterase (HuBuChE), anti-epileptic drugs and neutralizing decontamination solutions such as 0.5% hypochloriate are also used to treat such injuries.
- Treatments for cyanide poisoning include hydroxocobalamin, sodium nitrite, and rhodanase.
- M291 resin kits are also currently used to treat topical injuries resulting from exposure to chemical warfare agents. Any of these agents can be combined with the TRPA1 antagonists described herein.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound disclosed herein employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day.
- the dose can be 1-50, 1-25, or 5-10 mg/kg.
- Compounds that antagonize TRPA1 function may be useful in the prophylaxis and treatment of any of the foregoing injuries, diseases, disorders, or conditions.
- their efficacy can be readily tested in one or more animal models.
- Compounds that may reduce pain or other undesirable symptoms in the animals can be readily tested by observing behavioral and/or physical characteristics of challenged animals in the presence versus the absence of the test compound(s) or procedure.
- the mouse ear edema model provides a quantitative edema response as well as histopathological and biochemical endpoints as measurements of inflammation and tissue damage following exposure to the chemical warfare agent half mustard.
- the model is performed using CD-1 mice. Twenty-four hours following IP administration of test compound or vehicle, a solution of half mustard in organic solvent is applied to the inner surface of the right ear of each mouse. The left ear is not treated with half mustard and instead is maintained as a control. Animals are sacrificed at 24 hours, 72 hours, and 7 days post exposure to half mustard. The ear weights, draize scoring, and pathology are recorded at each time point.
- Half mustard injury in the mouse ear is measured by both edema response (fluid accumulation) and histopathological damage (necrosis, epidermal-dermal separation).
- test compound is administered therapeutically, e.g., immediately after, or one hour after exposure to half mustard.
- models can also be performed using sulfur mustard or nitrogen mustard instead of half mustard.
- a Guinea Pig model for Nerve Agent Challenge A Guinea pig model can be used to study the protective effects of the compounds against mortality induced by a nerve agent.
- the animals are pretreated with two IP doses of test compound, one IM dose of atropine, one IM dose of 2-PAM, or two IP doses of vehicle before challenge with 2 ⁇ LD50 (s.c.) of a nerve agent.
- the animals are observed at 6 observation times post challenge. The number of animals in each group surviving 24 hours post challenge is then recorded.
- test compound in an alternate model, is administered therapeutically, e.g., immediately after, or one hour after exposure to the nerve agent.
- the assay depended on detection of the rise in intracellular Ca 2+ concentration ([Ca 2+ ] i ) following channel activation in cells inducibly expressing the TRPA1 channel Ca 2+ rise was quantified with the use of fluorescent Ca 2+ indicators that were loaded into cells and thereafter indicated the [Ca 2+ ] i . Ca 2+ influx followed activation of the TRPA1 channel. Compounds inhibiting the [Ca 2+ ] i rise were considered hits for further investigation.
- TRPA1 construct specifically a construct encoding a TRPA1 protein with an amino acid sequence depicted in SEQ ID NO: 1 of WO 2007/073505
- TRPA1 construct a construct encoding a TRPA1 protein with an amino acid sequence depicted in SEQ ID NO: 1 of WO 2007/073505
- screened by conventional calcium imaging to find clones with TRPA1 expression following stimulation with 1 ⁇ g/ml tetracycline.
- These cells were maintained in the growth medium recommended by the manufacturer supplemented with 100 ⁇ g/ml hygromycin to promote retention of the TRPA1 construct.
- HBSS Hank's Balanced Salt Solution
- IC 50 values were determined for compounds defined as “hits.”
- the Fluo4 cell-based fluorescence assay was used to determine the intracellular Ca 2+ concentration in the presence of varying drug concentration.
- concentrations tested were 40 ⁇ M, 20 ⁇ M, 10 ⁇ M, 5 ⁇ M, 2.5 ⁇ M, 1.25 ⁇ M, and 0.625 ⁇ M.
- Compounds were tested in triplicate at all concentrations. Standard software was used to fit IC 50 curves.
- potency can be represented as % inhibition of a response in the presence (of a given concentration of compound) versus the absence of compound or in comparison to a control compound.
- efficacy can be represented as % inhibition of ion flux in the presence versus the absence of compound.
- Patch clamp experiments permit the detection of currents through the TRPA1 channel in the cell line described above.
- the whole-cell configuration of the patch clamp technique was used to test the compounds described herein.
- a glass electrode is brought into contact with a single cell and a high-resistance (gigaohm) seal is established with the cell membrane.
- the membrane is then ruptured to achieve the whole-cell configuration, permitting control of the voltage of the cell membrane and measurement of currents flowing across the membrane using the amplifier attached to the electrode and resulting in the replacement of cytoplasm with the pipette solution.
- HEK293/TREx TRPA1 cells were induced in the presence of 1 ⁇ g/ml tetracycline for 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separation) on glass coverslips for measurement. In some cases, cells were grown in low density overnight on glass coverslips. Potential blockers were tested for ability to block current in the continued presence of AITC.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paints Or Removers (AREA)
Abstract
Description
- This application claims priority from U.S. Ser. No. 61/127,666, U.S. Ser. No. 61/127,664, U.S. Ser. No. 61/127,665, U.S. Ser. No. 61/127,723, U.S. Ser. No. 61/127,787, U.S. Ser. No. 61/127,790, U.S. Ser. No. 61/127,682, all filed May 14, 2008, all of which are incorporated herein by reference in their entirety.
- The invention relates to compounds and compositions useful for treating injuries caused by chemical warfare and similar agents.
- A variety of ion channel proteins exist to mediate ion flux across cellular membranes. The proper expression and function of ion channel proteins is essential for the maintenance of cell function and intracellular communication. Numerous diseases and disorders are the result of misregulation of membrane potential or aberrant calcium handling. Given the central importance of ion channels in modulating membrane potential and ion flux in cells, identification of agents that can promote or inhibit particular ion channels are of great interest, both as research tools and as therapeutic agents.
- The present invention provides compounds and compositions for treating or preventing injuries resulting from chemical warfare agents by modulating the activity of the TRPA1 channel.
- In one aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (II) or a salt thereof
- wherein,
R1 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5; - R2 is H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5′;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, C(O), O, S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thionyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, hydroxyl alkoxyl, alkoxy alkoxyl, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6, wherein m is at least 2 when L is connected to the methylene carbon via a heteroatom,
each R9 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising
- administering to the subject a compound of Formula (III) or a salt thereof
- wherein,
R1 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5; - R2 is H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5′;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, C(O), S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryl, heteroaryl, cyclyl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, hydroxyl alkoxyl, alkoxy alkoxyl, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R9 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (IV) or a salt thereof
- wherein,
R1 and R2 are each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, C(O), S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, hydroxyl alkoxyl, alkoxy alkoxyl, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6;
each R9 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (V) or a salt thereof
- wherein,
R1 and R2 are each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, C(O), S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, hydroxyl alkoxyl, alkoxy alkoxyl, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
R9 is H, C1-C6 alkyl, or arylalkyl;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising
- administering to the subject a compound of Formula (VI) or a salt thereof
- wherein,
R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5;
R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or cyclyl, each of which is optionally substituted with 1-4 R5;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, C(O), S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, hydroxyl alkoxyl, alkoxy alkoxyl, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R9 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (VII) or a salt thereof
- wherein,
R1 and R2 are each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, C(O), S, S(O), S(O)2, NR6, CH2, cyclyl, aryl, heterocyclyl, or heteroaryl;
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryl, heteroaryl, cyclyl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, hydroxyl alkoxyl, alkoxy alkoxyl, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each m and n are independently 0, 1, 2, 3, 4, 5, or 6. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (IX) or a salt thereof
- wherein,
R1 and R2 are each independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5;
L is NR6SO2, SO2NR6, OC(O)NR6, NR6C(O)O, NR6C(O)NR6, NR6C(O), C(O)NR6, O, S, S(O), S(O)2, NR6, or CH2,
R3 is cyclyl, heterocyclyl, aryl, heteroaryl, each of which is optionally substituted with 1-4 R7;
each R5 is independently halo, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, amido, alkylamido, dialkylamido, thioyl, sulfonyl, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R6 is independently H, C1-C6 alkyl, arylalkyl, S(O)alkyl, acetyl, amidyl, or S(O)H;
each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, hydroxyl alkoxyl, alkoxy alkoxyl, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, thioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea acyl, nitro, cyano, cyclyl, heterocyclyl, aryl, or heteroaryl;
each R9 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, halo, hydroxyl, alkoxy, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, thioyl, alkylthioyl, sulfonyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro, cyano, each of which is independently substituted with 1-3 R8;
m is 1, 2, 3, 4, 5, or 6. - In another aspect, the invention features a method of treating an injury resulting from exposure to a chemical warfare agent in a subject, such as a human, the method comprising administering to the subject a compound of Formula (X) or a salt thereof
- wherein
W represents O or S;
R, independently for each occurrence, represents H or lower alkyl;
R′ represents substituted or unsubstituted alkyl or substituted or unsubstituted aryl;
E represents carboxylic acid (CO2H), ester or amide; and
Ar represents a substituted or unsubstituted aryl ring.
Exemplary compounds of Formula X are described in WO 2007/073505. - In one aspect, the invention features a method of treating a subject who has been exposed to a chemical warfare agent, the method comprising administering to a subject an effective amount of a compound of Formula (II), (III), (IV), (V), (VI), (VII), (IX) or (X), or a salt thereof. In some embodiments the treatment reduces the severity of injury resulting from the exposure to the chemical warfare agent.
- In some embodiments, the compound is administered orally, via intramuscular injection, by topical ocular administration, topically, or by inhalation. In some embodiments, the subject being treated is a human.
- The term “acyl” refers to a group represented by the general formula hydrocarbylC(O)—, preferably alkylC(O)—.
- The term “acylamino” refers to a moiety that can be represented by the general formula:
- wherein R9 is as defined below, and R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m-R8, where m and R8 are as defined herein.
- The term “aliphatic group” refers to a straight-chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, and an alkynyl group.
- The term “alkenyl,” as used herein, refers to an aliphatic group containing at least one double bond.
- The terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined below, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen.
- The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl(alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains), and more preferably 20 or fewer, and most preferably 10 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- The term “alkynyl”, as used herein, refers to an aliphatic group containing at least one triple bond.
- The term “alkylthio” refers to a hydrocarbyl group having a sulfur radical attached thereto. In some embodiments, the “alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, or —S-alkynyl. Representative alkylthio groups include methylthio, ethylthio, and the like.
- The terms “amine” and “amino” refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:
- wherein R9, R10 and R′10 each independently represent a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, an alkoxy, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.
- The term “amido” refers to a moiety that can be represented by the general formula:
- wherein R9, R10 are as defined above.
- The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
- The term “aryl” as used herein includes 5-, 6-, and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, polycyclyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, —CF3, —CN, or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- The term “carbocycle or cyclyl,” as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
- The term “carbonyl” refers to moieties represented by the general formula:
- wherein X is a bond or represents an oxygen or a sulfur, and R11 represents a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8 or a pharmaceutically acceptable counter-ion, R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above. Where X is an oxygen and R11 or R′11 is not hydrogen, the formula represents an “ester”. Where X is an oxygen, and R11 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R11 is a hydrogen, the formula represents a “carboxylic acid”. Where X is an oxygen, and R′11 is hydrogen, the formula represents a “formate”. In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a “thiocarbonyl” group. Where X is a sulfur and R11 or R′11 is not hydrogen, the formula represents a “thioester.” Where X is a sulfur and R11 is hydrogen, the formula represents a “thiocarboxylic acid.” Where X is a sulfur and R11′ is hydrogen, the formula represents a “thioformate.” On the other hand, where X is a bond, and R11 is not hydrogen, the above formula represents a “ketone” group. Where X is a bond, and R11 is hydrogen, the above formula represents an “aldehyde” group.
- The term “ester”, as used herein, refers to a group —C(O)OR9 wherein R9 represents a hydrocarbyl group.
- The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
- The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
- The terms “heterocyclyl” or “heterocyclic group” refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles. The term “heterocyclyl” or “heterocyclic group” includes “heteroaryl” and “saturated or partially saturated heterocyclyl” structures. The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). Any ring atom can be substituted (e.g., by one or more substituents). The term “saturated or partially saturated heterocyclyl” refers to a non-aromatic cyclic structure that includes at least one heteroatom. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
- The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.
- The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a ═O or ═S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a ═O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
- As used herein, the term “nitro” means —NO2; the term “halogen” designates —F, —Cl, —Br or —I; the term “sulfhydryl” means —SH; the term “hydroxyl” means —OH; and the term “sulfonyl” means —SO2-.
- The terms “polycyclyl” or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
- Exemplary monocyclic rings include furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, and trithiane.
- Exemplary bicyclic rings include indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indenyl, naphthalenyl, azulenyl, imidazopyridazionyl, pyrazolopyrimidinedionyl, or pyrrolopyrimidinedionyl moieties.
- Exemplary tricyclic rings include carbazole, acridine, phenazine, phenothiazine, phenoxazine, fluorine, and anthracene.
- The phrase “protecting group” as used herein means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).
- The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF3, —CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF3, —CN, and the like. Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.
- The term “sulfate” refers to a moiety that can be represented by the general formula:
- in which R41 is as defined herein.
- The term “sulfonamido” refers to a moiety that can be represented by the general formula:
- in which R9 and R′11 are as defined above.
- The term “sulfonate” refers to a moiety that can be represented by the general formula:
- in which R41 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
- The terms “sulfoxido” or “sulfinyl,” as used herein, refers to a moiety that can be represented by the general formula —S(═O)—R44, in which R44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
- The term “thioester,” as used herein, refers to a group —C(O)SR9 or —SC(O)R9 wherein R9 represents a hydrocarbyl.
- As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
- Exemplary monocyclic rings include furan, thiophene, pyrrole, pyrroline, pyrrolodine, oxazole, thiazole, imidazole, imidazoline, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, and trithiane.
- Exemplary bicyclic rings include indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indenyl, naphthalenyl, azulenyl, imidazopyridazionyl, pyrazolopyrimidinedionyl, or pyrrolopyrimidinedionyl moieties.
- Exemplary tricyclic rings include carbazole, acridine, phenazine, phenothiazine, phenoxazine, fluorine, and anthracene.
- The terms “antagonist” and “inhibitor” are used interchangeably to refer to an agent that decreases or suppresses a biological activity, such as to repress an activity of an ion channel, such as TRPA1. TRPA1 inhibitors include inhibitors having any combination of the structural and/or functional properties disclosed herein.
- An “effective amount” of, e.g., a TRPA1 antagonist, with respect to the subject methods of treatment, refers to an amount of the antagonist in a preparation which, when applied as part of a desired dosage regimen brings about a desired clinical or functional result. Without being bound by theory, an effective amount of a TRPA1 antagonist for use in the methods of the present invention, includes an amount of a TRPA1 antagonist effective to decrease one or more in vitro or in vivo functions of a TRPA1 channel. Exemplary functions include, but are not limited to, membrane polarization (e.g., an antagonist may promote hyperpolarization of a cell), ion flux, ion concentration in a cell, outward current, and inward current. Compounds that antagonize TRPA1 function include compounds that antagonize an in vitro or in vivo functional activity of TRPA1. When a particular functional activity is only readily observable in an in vitro assay, the ability of a compound to inhibit TRPA1 function in that in vitro assay serves as a reasonable proxy for the activity of that compound. In certain embodiments, an effective amount is an amount sufficient to inhibit a TRPA1-mediated current and/or the amount sufficient to inhibit TRPA1 mediated ion flux.
- The term “preventing,” when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition or injury in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount. Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population. Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
- The term “prodrug” is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity in the host animal.
- Exemplary compounds are provided in Table 1-7.
- Compounds of Formula II include those shown in Table 1.
-
TABLE 1 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (1-methyl-6-oxo-1H-purin- 7(6H)-yl)acetamide N-(4-(3,4- dimethylphenyl)thiazol-2-yl)-2- (1-methyl-6-oxo-1H-purin- 7(6H)-yl)acetamidede N-(5-(3,4-difluorophenyl)-3H- pyrrol-2-yl)-2-(1-methyl-6-oxo- 1H-purin-7(6H)-yl)acetamide 2-(1-methyl-6-oxo-1H-purin 7(6H)-yl)-N-(4-p-tolylthiazol- 2-yl)acetamide N-(4-(4-fluorophenyl)thiazol-2- yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(4-ethylphenethyl)-2-(1- methyl-6-oxo-1H-purin-7(6H)- yl)acetamide 2-(1-methyl-6-oxo-1H-purin- 7(6H)-yl)-N-(4- methylphenethyl)acetamide N-(4-methoxyphenethyl)-2-(1- methyl-6-oxo-1H-purin-7(6H)- yl)acetamide N-(4-isopropylphenyl)-2-(1- methyl-6-oxo-1H-purin-7(6H)- yl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-fluorobenzo[d]thiazol-2- yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-methoxybenzo[d]thiazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]thiazol-2-yl)- 2-(1-methyl-6-oxo-1H-purin- 7(6H)-yl)acetamide N-(6-fluorobenzo[d]oxazol-2- yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-methoxybenzo[d]oxazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(1-methyl-6-oxo-1H- purin-7(6H)-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]oxazol-2-yl)- 2-(1-methyl-6-oxo-1H-purin- 7(6H)-yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(1,3-dimethyl-2,6-dioxo-2,3- dihydro-1H-purin-7(6H)- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(1,3-dimethyl-2,6-dioxo-2,3- dihydro-1H-purin-7(6H)- yl)acetamide N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4-p- tolylthiazol-2-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4-(4- fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4- ethylphenethyl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4- methylphenethyl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4- methoxyphenethyl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(4- isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4-oxo- 4,5-dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6- fluorobenzo[d]thiazol-2- yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6- methoxybenzo[d]thiazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4-oxo- 4,5-dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4-oxo- 4,5-dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6- fluorobenzo[d]oxazol-2- yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6- methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(5,7-dimethyl-4-oxo- 4,5-dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(5,7-dimethyl-4-oxo- 4,5-dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)-N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(5,7-dimethyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide N-(4-(3,4- dimethylphenyl)thiazol-2-yl)-2- (5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)-N-(5-p-tolyl-3H-pyrrol-2- yl)acetamide N-(4-(4-fluorophenyl)thiazol-2- yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazol[4,5- c]pyridin-3-yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazol[4,5- c]pyridin-3-yl)acetamide N-(4-ethylphenethyl)-2-(5- methyl-4-oxo-4,5-dihydro-3H- imidazol[4,5-c]pyridin-3- yl)acetamide 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazol[4,5-c]pridin-3- yl)-N-(4- methylphenethyl)acetamide N-(4-methoxyphenethyl)-2-(5- methyl-4-oxo-4,5-dihydro-3H- imidazol[4,5-c]pyridin-3- yl)acetamide N-(4-isopropylphenyl)-2-(5- methyl-4-oxo-4,5-dihydro-3H- imidazol[4,5-c]pyridin-3- yl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazol[4,5- c]pyridin-3-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazol[4,5- c]pyridin-3-yl)acetamide N-(6-fluorobenzo[d]thiazol-2- yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(6-methoxybenzo[d]thiazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]thiazol-2-yl)- 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide N-(6-fluorobenzo[d]oxazol-2- yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(6-methoxybenzo[d]oxazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(5-methyl-4-oxo-4,5- dihydro-3H-imidazo[4,5- c]pyridin-3-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]oxazol-2-yl)- 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(5-methyl-4-oxo-4,5-dihydro- 3H-imidazo[4,5-c]pyridin-3- yl)acetamide -
TABLE 2 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazol[4,5-b]pyrazin-1- yl)acetamide N-(4-(3,4- dimethylphenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyrazin-1- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyrazin-1- yl)acetamide 2-(4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyrazin-1-yl)- N-(4-p-tolylthiazol-2- yl)acetamide N-(4-(4-fluorophenyl)thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyrazin-1-yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyrazin-1-yl)acetamide N-(4-ethylphenethyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyrazin-1- yl)acetamide 2-(4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyrazin-1-yl)- N-(4-methylphenethyl)acetamide N-(4-methoxyphenethyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyrazin-1- yl)acetamide N-(4-isopropylphenyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyrazin-1- yl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyrazin-1-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyrazin-1-yl)acetamide N-(6-fluorobenzo[d]thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-methoxybenzo[d]thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-fluorobenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-methoxybenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]oxazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4-p- tolylthiazol-2-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4-(4- fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4- ethylphenethyl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4- methylphenethyl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4- methoxyphenethyl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(4- isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4,7-dimethyl-5-oxo-4,5 dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6- fluorobenzo[d]thiazol-2- yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6- methoxybenzo[d]thiazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)-2- (4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6- fluorobenzo[d]oxazol-2- yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6- methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide 2-(4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)-N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)-2- (4,7-dimethyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(4-(3,4- dimethylphenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide 2-(4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1-yl)- N-(4-p-tolylthiazol-2- yl)acetamide N-(4-(4-fluorophenyl)thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(4-ethylphenethyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyridin-1- yl)acetamide 2-(4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1-yl)- N-(4-methylphenethyl)acetamide N-(4-methoxyphenethyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyridin-1- yl)acetamide N-(4-isopropylphenyl)-2-(4- methyl-5-oxo-4,5-dihydro-1H- imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-fluorobenzo[d]thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-methoxybenzo[d]thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-fluorobenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-methoxybenzo[d]oxazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4-methyl-5-oxo-4,5- dihydro-1H-imidazo[4,5- b]pyridin-1-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]oxazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)-2- (4-methyl-5-oxo-4,5-dihydro- 1H-imidazo[4,5-b]pyridin-1- yl)acetamide - Compounds of Formula IV include those shown in Table 3.
-
TABLE 3 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4,6-dimethyl-5,7-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[4,3- d]pyrimidin-1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4,6-dimethyl-5,7-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[4,3- d]pyrimidin-1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4-p-tolylthiazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4-(4-fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4-ethylphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4- methylphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4- methoxyphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(4-isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-fluorobenzo[d]thiazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-methoxybenzo[d]thiazol- 2-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-fluorobenzo[d]oxazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1-yl)- N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[4,3-d]pyrimidin-1- yl)acetamide - Compounds of Formula V include those shown in Table 4.
-
TABLE 4 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (5,7-dimethyl-4,6-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[3,4- d]pyrimidin-3-yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (5,7-dimethyl-4,6-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[3,4- d]pyrimidin-3-yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4-p-tolylthiazol-2- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4-(4-fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4-ethylphenethyl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4- methylphenethyl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4- methoxyphenethyl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(4-isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-fluorobenzo[d]thiazol-2- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-methoxybenzo[d]thiazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)-2- (5,7-dimethyl-4,6-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[3,4- d]pyrimidin-3-yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-fluorobenzo[d]oxazol-2- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3- yl)acetamide 2-(5,7-dimethyl-4,6-dioxo- 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-d]pyrimidin-3-yl)- N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)-2- (5,7-dimethyl-4,6-dioxo-4,5,6,7- tetrahydro-1H-pyrazolo[3,4- d]pyrimidin-3-yl)acetamide - Compounds of Formula VI include those shown in Table 5.
-
TABLE 5 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4-p-tolylthiazol-2- yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4-(4- fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4- ethylphenethyl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4- methylphenethyl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4- methoxyphenethyl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(4- isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4,5-dimethyl-6-oxo- 5,6-dihydropyrrolo[3,2- d]imidazol-1(4H)-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6- fluorobenzo[d]thiazol-2- yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6- methoxybenzo[d]thiazol-2- yl)acetamide (E)-N-(5-(2,3-dichloroprop-1- enyl)thiazol-2-yl)-2-(4,5- dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4,5-dimethyl-6-oxo- 5,6-dihydropyrrolo[3,2- d]imidazol-1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6- fluorobenzo[d]oxazol-2- yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6- methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4,5-dimethyl-6-oxo- 5,6-dihydropyrrolo[3,2- d]imidazol-1(4H)-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4,5-dimethyl-6-oxo- 5,6-dihydropyrrolo[3,2- d]imidazol-1(4H)-yl)acetamide 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)-N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(4,5-dimethyl-6-oxo-5,6- dihydropyrrolo[3,2-d]imidazol- 1(4H)-yl)acetamide - Compounds of Formula VII include those shown in Table 6.
-
TABLE 6 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4-(3,4- dimethylphenyl)thiazol-2- yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4-p-tolylthiazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4-(4- fluorophenyl)thiazol-2- yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- l-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4- ethylphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4- methylphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4- methoxyphenethyl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(4- isopropylphenyl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7- dioxo-4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro)-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6- fluorobenzo[d]thiazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6- methoxybenzo[d]thiazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7- dioxo-4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(4,6-dimethyl-5,7- dioxo-4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6-fluoro-5- methoxybenzo[d]thiazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6- fluorobenzo[d]oxazol-2- yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6- methoxybenzo[d]oxazol-2- yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(4,6-dimethyl-5,7- dioxo-4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(4,6-dimethyl-5,7- dioxo-4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)-N-(6-fluoro-5- methoxybenzo[d]oxazol-2- yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)- 2-(4,6-dimethyl-5,7-dioxo- 4,5,6,7-tetrahydro-1H- [1,2,3]triazolo[4,5-d]pyrimidin- 1-yl)acetamide - Compounds of Formula IX include those shown in Table 7.
-
TABLE 7 N-(4-(3,4- dichlorophenyl)thiazol-2-yl)-2- (3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(4-(3,4- dimethylphenyl)thiazol-2-yl)-2- (3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(4-(3,4- difluorophenyl)thiazol-2-yl)-2- (3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide 2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)-N-(4-p- tolylthiazol-2-yl)acetamide N-(4-(4-fluorophenyl)thiazol-2- yl)-2-(4-methyl-5-oxo-4,5- dihydroimidazo[4,5-b]pyrazin- 1-yl)acetamide N-(4-(4-chlorophenyl)thiazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(4-ethylphenethyl)-2-(3- methyl-2-oxo-2,3-dihydropurin- 7-yl)acetamide N-(4-methylphenethyl)-2-(3- methyl-2-oxo-2,3-dihydropurin- 7-yl)acetamide N-(4-methoxyphenethyl)-2-(3- methyl-2-oxo-2,3-dihydropurin- 7-yl)acetamide N-(4-isopropylphenyl)-2-(3- methyl-2-oxo-2,3-dihydropurin- 7-yl)acetamide N-(6-tert-butylbenzo[d]thiazol- 2-yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-chlorobenzo[d]oxazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-fluorobenzo[d]thiazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-methoxybenzo[d]thiazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(5,6-dichlorobenzo[d]thiazol- 2-yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(5,6-difluorobenzo[d]thiazol- 2-yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]thiazol-2-yl)- 2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-chloro-5- methoxybenzo[d]thiazol-2-yl)- 2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-fluorobenzo[d]oxazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-methoxybenzo[d]oxazol-2- yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(5,6-dichlorobenzo[d]oxazol- 2-yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(5,6-difluorobenzo[d]oxazol- 2-yl)-2-(3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-fluoro-5- methoxybenzo[d]oxazol-2-yl)-2- (3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide N-(6-chloro-5- methoxybenzo[d]oxazol-2-yl)-2- (3-methyl-2-oxo-2,3- dihydropurin-7-yl)acetamide - Certain compounds disclosed herein may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For example, if one chiral center is present in a molecule, the invention includes racemic mixtures, enantiomerically enriched mixtures, and substantially enantiomerically pure compounds. The composition can contain, e.g., more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, or more than 99% of a single enantiomer.
- The “enantiomeric excess” or “% enantiomeric excess” of a composition can be calculated using the equation shown below. In the example shown below a composition contains 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, i.e., the R enantiomer.
-
ee=(90−10)/100=80%. - Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%.
- Methods of preparing substantially isomerically pure compounds are known in the art. If, for instance, a particular enantiomer of a compound disclosed herein is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts may be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers. Alternatively, enantiomerically enriched mixtures and pure enantiomeric compounds can be prepared by using synthetic intermediates that are enantiomerically pure in combination with reactions that either leave the stereochemistry at a chiral center unchanged or result in its complete inversion. Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are well known in the art, and it is well within the ability of one of skill in the art to choose an appropriate method for a particular situation. See, generally, Furniss et al. (eds.), Vogel's Encyclopedia of Practical Organic Chemistry 5th Ed., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and Heller, Acc. Chem. Res. 23: 128 (1990).
- The compounds described herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention. For example, deuterated compounds and compounds incorporated 13C are intended to be encompassed within the scope of the invention.
- Certain compounds disclosed herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds disclosed herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- As set out above, certain embodiments of the present compounds may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term “pharmaceutically acceptable salts” in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds disclosed herein. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19.)
- In other cases, the compounds disclosed herein may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds disclosed herein. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (See, for example, Berge et al., supra).
- An antagonist of TRPA1 function may inhibit the outward current, the inward current, or both currents. Compounds that inhibit both currents may do so with the same or with differing IC50 values. The inhibition of a particular current is measured by the ability to inhibit or reduce such current (e.g., inward and/or outward) in an in vitro or an in vivo assay. Compounds that inhibit any of the foregoing currents in an in vitro or in vivo assay are characterized as compounds that inhibit a function of TRPA1. Additionally or alternatively, a further exemplary function of TRPA1 that may be inhibited by the present compounds is ion flux mediated by TRPA1.
- A compound described herein (e.g., a TRPA1 antagonist) can be chosen for a use described herein may be chosen because it inhibits a TRPA1 function with an IC50 less than or equal to 10 uM, 5 uM, 1 uM, or less than or equal to 700, 600, 500, 400, 300, 250, 200, or 100 nM. In other embodiments, the compound described herein inhibits a TRPA1 function with an IC50 less than or equal to 75 nM, less than or equal to 50 nM, or less than or equal to 25, 10, 5, or 1 nM.
- In certain embodiments, inhibition of TRPA1 function means that a function, for example a TRPA1 mediated current, is decreased by greater than 50% in the presence of an effective amount of a compound in comparison to in the absence of the compound or in comparison to an ineffective amount of a compound. In certain other embodiments, the inhibition of a TRPA1 function means that a function, for example a TRPA1 mediated current or TRPA1 mediated ion flux, is decreased by at least 50%, 60%, 70%, 75%, 80%, 85%, or 90% in the presence of an effective amount of a compound in comparison to in the absence of the compound. In still other embodiments, the inhibition of a TRPA1 function means that a function, for example a TRPA1 mediated current, is decreased by at least 92%, 95%, 97%, 98%, 99%, or 100% in the presence of an effective amount of a compound in comparison to in the absence of the compound.
- some embodiments, a compound described herein (e.g., a TRPA1 antagonist) can be characterized by some level of activity versus other ion channels (e.g., certain compounds are selective for inhibiting TRPA1 and other compounds exhibit a level of cross reactivity against one or more other ion channel). When a compound described herein is characterized by its activity against another ion channel, inhibition of a function or activity of the other ion channel is defined analogously to the way in which a function of a TRPA1 channel is defined. Thus, inhibiting the function of another ion channel means, for example, inhibiting ion flux mediated by that other ion channel or inhibiting the current mediated by that other ion channel.
- In some embodiments, a compound described herein (e.g., a TRPA1 antagonist) is chosen for use because it is more selective for one TRP isoform than others, e.g., 10-fold, and more preferably at least 20, 40, 50, 60, 70, 80, or at least 100- or 1000-fold more selective for TRPA1 over one or more of TRPC6, TRPV5, TRPV6, TRPM8, TRPV1, TRPV2, TRPV4, and/or TRPV3. In other embodiments, the differential is smaller, e.g., it more strongly inhibits TRPA1 than TRPM8, TRPV1, TRPV2, TRPV3, and/or TRPV4, preferably at least twice, three times, five times, or ten times more strongly. Such comparisons may be made, for example, by comparing IC50 values.
- In other embodiments, a compound described herein (e.g., a TRPA1 antagonist) is chosen for use because it is more selective for TRPA1 than for other non-TRP ion channels, e.g., 10-fold, and more preferably at least 20, 40, 50, 60, 70, 80, or at least 100- or 1000-fold more selective for TRPA1 over one or more of NaV1.2, Cav1.2, Cav3.1, HERG, and/or mitochondrial uniporter. In other embodiments, the differential is smaller, e.g., it more strongly inhibits TRPA1 than NaV1.2, Cav1.2, Cav3.1, HERG, and/or mitochondrial uniporter, preferably at least twice, three times, five times, or ten times more strongly.
- In certain embodiments, the compound described herein (e.g., a TRPA1 antagonist) inhibits TRPA1 with an IC50 at least one order of magnitude more potent than its Ki for the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. In certain other embodiments, the compound described herein inhibits TRPA1 with an IC50 at least two orders of magnitude, three orders of magnitude, or four orders of magnitude more potent than its Ki for the AMPA receptor. In certain embodiments, the compound described herein does not appreciably bind the AMPA receptor. In other words, the compound described herein inhibits TRPA1 with a particular IC50 and, when administered at that concentration, the antagonist does not appreciably bind the AMPA receptor.
- In certain embodiment, a compound is chosen because it antagonizes the function of TRPA1 and the function of TRPM8, TRPV1 and/or TRPV3. Although such compounds selectively antagonize the function of more than one ion channel, the IC50 values for the different ion channels need not be identical.
- The IC50 values are measured in vitro using, for example, patch clamp analysis or standard measurements of calcium flux. Exemplary in vitro methods for calcium flux-based IC50 estimation are described in Example 2. Methods used to obtain more definitive IC50 measurements are described in Example 3. Alternatively, estimates of % inhibition of current or ion flux can also be calculated and used to assess efficacy of a compound as an inhibitor.
- Movement of ions across cellular membranes is carried out by specialized proteins. TRP channels are one large family of non-selective cation channels that function to help regulate ion flux and membrane potential. Non-selective cation channels such as TRPA1 modulate the flux of calcium and sodium ions across cellular membranes. Sodium and calcium influx leads to depolarization of the cell. This increases the probability that voltage-gated ion channels will reach the threshold required for activation. As a result, activation of non-selective cation channels can increase electrical excitability and increase the frequency of voltage-dependent events. Voltage-dependent events include, but are not limited to, neuronal action potentials, cardiac action potentials, smooth muscle contraction, cardiac muscle contraction, and skeletal muscle contraction.
- Calcium influx caused by the activation of non-selective cation channels such as TRPA1 also alters the intracellular free calcium concentration. Calcium is a ubiquitous second messenger molecule within the cell, so alterations in intracellular calcium levels have profound effects on signal transduction and gene expression. As a result, activation of non-selective cation channels such as TRPA1 can lead to changes in gene expression and cellular phenotype. Gene expression events include, but are not limited to, production of mRNAs encoding cell surface receptors, ion channels, and kinases. These changes in gene expression can lead to hyperexcitability in that cell.
- Modulating the function of TRPA1 proteins provides a means of modulating calcium homeostasis, sodium homeostasis, membrane polarization, and/or intracellular calcium levels, and compounds that can modulate TRPA1 function are useful in many aspects, including, but not limited to, maintaining calcium homeostasis, modulating intracellular calcium levels, modulating membrane polarization, and treating or preventing diseases, disorders, or conditions associated with calcium and/or sodium homeostasis or dyshomeostasis.
- Bautista et al. have reported that TRPA1 mediates the inflammatory actions of agents such as acrolein, which causes the inflammatory and toxic actions of tear gas. (Bautista et al., Cell (2006) 124:1269-82.) Bessac et al. have shown that hypochlorite—the main mediator of chlorine irritancy—activates Ca2+ influx and membrane currents in sensory neurons cultured from Trpa1+/+ mice, while the influx of Ca2+ was absent in neurons cultured from Trpa1−/− mice. In addition, Bessac et al. compared the responses of Trpa1+/+ mice and Trpa1−/− mice to NaOCl exposure. The Trpa1+/+ mice showed much more respiratory depression than did the Trpa1−/− mice. (Bessac et al., Journal of Clinical Investigation (2008) 18:1899-1910) These data suggest that TRPA1 antagonists could be useful to treat or prevent the effects of chemical warfare agents including tear gas and chlorine.
- A subject may be exposed to a chemical warfare agent, e.g., by inhalation or by contact with the skin. If a compound described herein (e.g., a TRPA1 antagonist) is administered, the symptoms or injuries resulting from the exposure to the chemical warfare agents can be reduced, prevented, or both. The compound described herein can be administered to a subject before, during, or following such exposure and is therefore administered within 24 hours, 18 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 10 minutes, 5 minutes, one minute, or thirty seconds before or after such exposure. The TRPA1 anta compound described herein gonist can be administered prophylactically, when exposure to an agent is anticipated. It can also be administered after exposure to the chemical warfare agent (e.g., before or after symptoms of injury present in a subject).
- Injuries resulting from the exposure to chemical warfare agents are known in the art and include any physical injuries, such as injuries to the skin, eyes, respiratory tract, musculo-skeletal system, circulatory system, gastrointestinal tract, central nervous system, peripheral nervous system, heart, liver, lungs, and kidneys. Exemplary symptoms or injuries resulting from the exposure to chemical warfare agents include inflammation, burn, itch, pain, rash, blisters, sweating, muscle twitching, nausea, vomiting, diarrhea, weakness, loss of consciousness, convulsions, muscular twitching, paralysis, secretions (from the mouth, nose, or lung for example), difficulty breathing, blurred vision, eye pain, lacrimation, red eyes, shortness of breath, coughing, phlegm production and narrowing of the airways, headaches, tremors, dizziness, numbness or tingling, anxiety, insomnia, depression, emotional instability, and even death. The term “chemical warfare agent” includes all of those agents classified as schedule 1, 2, and 3 agents under the Chemical Weapons Convention of 1993 and may be in liquid form, gas form, solid form, or combinations thereof. Exemplary agents are described in further detail below and include, for example, nerve agents, blood agents, blister agents, pulmonary agents, incapacitating agents, and toxins. Other agents include methyl isocyanate, hexamethylene diisocyanate, 2,4-toluene-diisocyanate, and diphenylmethane-4,4-diisocyanate (MDI).
- Nerve agents. Nerve agent poisoning typically leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles. These symptoms are reduced or prevented by the administration of the TRPA1 antagonists. Exemplary agents include G agents such as tabun (GA), sarin (GB), soman (GD), cyclosarin (GF), and GV; V agents such as VE, VG, VM, VX, and Novichok agents.
- Blood agents. A blood agent (or cyanogen agent) is a compound containing a cyanide group that prevents the body from utilizing oxygen. These agents exert their toxic effect at the cellular level by directly interrupting cellular respiration. Exemplary agents include cyanogen chloride, hydrogen cyanide, and hydrogen sulfide.
- Blister agents. Blister agents or vesicants typically cause severe skin, eye and mucosal pain and irritation. These agents also have the ability to cause large, painful water blisters. Blister agents include, for example, lewisites, nitrogen mustard, sulfur mustard, ethyldichloroarsine (a lewisite analog; ED), methyldichloroarsine (MD), phenyldichloroarsine (PD), and phosgene oxime (CX). Lewisites include, for example, 2-Chlorovinyldichloroarsine (Lewisite 1), Bis(2-chlorovinyl)chloroarsine (Lewisite 2), and Tris(2-chlorovinyl)arsine (Lewisite 3). Exemplary nitrogen mustards are bis(2-chloroethyl)ethylamine (HN1), bis(2-chloroethyl)methylamine (HN2), and tris(2-chloroethyl)amine (HN3). Sulfur mustards include, for example, 1,2-Bis(2-chloroethylthio)ethane (Sesquimustard; Q), 1,3-Bis(2-chloroethylthio)-n-propane, 1,4-Bis(2-chloroethylthio)-n-butane, 1,5-Bis(2-chloroethylthio)-n-pentane, 2-Chloroethylchloromethylsulfide, bis(2-chloroethyl) sulfide (Mustard gas; HD), bis(2-chloroethylthio) methane, bis(2-chloroethylthiomethyl)ether, and bis(2-chloroethylthioethyl)ether (0 Mustard).
- Pulmonary agents. A pulmonary agent (or choking agent) is a chemical weapon agent designed to impede a subject's ability to breathe, resulting in suffocation. Exemplary agents include adamsite (DM), acrolein, bis(chloromethyl)ether (BCME), chlorine (Cl2), chloropicrin (PS), diphosgene (DP), methyl chlorosulfonate, phosgene (CG), and stannic chloride.
- Incapacitating agents. Incapacitating agents or riot-control agents typically produce temporary physiological or mental effects, or both, such that individuals who are exposed to them are incapable of concerted effort. Upon their exposure, lachrymatory agents (or lachrymators) for example, irritate the eyes to cause tearing, pain, and even temporary blindness. The most common lachrymatory agents are tear gas and pepper spray and include, for example, a-Chlorotoluene, benzyl bromide, bromoacetone (BA), bromobenzylcyanide (CA) bromomethyl ethyl ketone, capsaicin (OC), chloracetophenone (Tear gas; CN), chloromethyl chloroformate, dibenzoxazepine (CR), ethyl iodoacetate, ortho-chlorobenzylidene malononitrile (Super tear gas; CS), trichloromethyl chloroformate, and xylyl bromide. Other incapacitating agents include, for example, 3-Quinuclidinyl benzilate (psychedelic; BZ), hydrocyanic acid (paralytic), diphenylchloroarsine (sternutatory; DA), diphenylcyanoarsine (DC), and KOLOKOL-1 (tranquilizer).
- Toxins. Exemplary toxins are abrin, ricin, and saxitoxin.
- While it is possible for a compound disclosed herein to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation, where the compound is combined with one or more pharmaceutically acceptable excipients or carriers. The compounds disclosed herein may be formulated for administration in any convenient way for use in human or veterinary medicine. In certain embodiments, the compound included in the pharmaceutical preparation may be active itself, or may be a prodrug, e.g., capable of being converted to an active compound in a physiological setting.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Examples of pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; (21) cyclodextrins such as Captisol®; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.
- Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- Solid dosage forms (e.g., capsules, tablets, pills, dragees, powders, granules and the like) can include one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents.
- Liquid dosage forms can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- The tablets, and other solid dosage forms of the pharmaceutical compositions disclosed herein, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- The formulations disclosed herein can be delivered via a device. Exemplary devices include, but are not limited to, a catheter, wire, stent, or other intraluminal device. Further exemplary delivery devices also include a patch, bandage, mouthguard, or dental apparatus. Transdermal patches have the added advantage of providing controlled delivery of a compound disclosed herein to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Another example of a device is a metered dose aerosol dispenser containing an aerosol pharmaceutical composition for pulmonary or nasal delivery comprising an agent that inhibits a TRPA1-mediated current with an IC50 of 1 micromolar or less. For instance, it can be a metered dose inhaler, a dry powder inhaler or an air-jet nebulizer.
- Ophthalmic formulations, eye ointments, drops, solutions and the like, are also contemplated as being within the scope of this invention.
- In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- When the compounds disclosed herein are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- The formulations can be administered topically, orally, transdermally, rectally, vaginally, parentally, intranasally, intrapulmonary, intraocularly, intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intracardiacly, intradermally, intraperitoneally, transtracheally, subcutaneously, subcuticularly, intraarticularly, subcapsularly, subarachnoidly, intraspinally, intrasternally or by inhalation.
- Particularly useful modes of administration include topical administration, intramuscular injection, inhalation, topical ocular administration (e.g., via eye drops), or oral administration.
- Another aspect of the invention provides a conjoint therapy wherein one or more other therapeutic agents are administered with a compound described herein (e.g., a TRPA1 modulator such as an antagonist). Such conjoint treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of the treatment.
- In certain embodiments, two or more compounds of the invention are conjointly administered. When two or more compounds of the invention are conjointly administered, the two or more compounds may have a similar selectivity profile and functional activity, or the two or more compounds may have a different selectivity profile and functional activity. By way of example, the two or more compounds may both be approximately 10, 100, or 1000 fold selective for antagonizing a function of TRPA1 over TRPV1, TRPV5, and TRPV6 (e.g., the two or more compounds have a similar selectivity profile), and further may inhibit a function of TRPA1 with a similar IC50 (e.g., a similar functional activity). Alternatively, the one of the two or more compounds may selectively inhibit TRPA1 while the other of the two or more compounds inhibits both TRPA1 and TRPV1 (e.g., the two or more compounds have differing selectivity profiles). Administration of combinations of two or more compounds of the invention having similar or differing properties are contemplated.
- In certain embodiments, a compound of the invention is conjointly administered with one or more additional compounds that antagonize the function of a different channel. By way of example, a compound of the invention may be conjointly administered with one or more compounds that antagonize TRPV1, TRPM8, and/or TRPV3. The compound(s) that antagonize TRPV1, TPRM8, or TRPV3 may be selective for TRPV1, TRPM8 or TRPV3 (e.g., inhibit TRPV1 or TRPV3 10, 100, or 1000 fold more strongly than TRPA1). Alternatively, the compound(s) that antagonize TRPV1 or TRPV3 may cross react with other TRP channels.
- In certain other embodiments, a compound of the invention is conjointly administered with one or more additional agents or therapeutic regimens appropriate for the particular injury being treated. For example, current treatments for injuries caused by exposure to nerve agents include treatment with atropine and Pralidoxime chloride (2-PAM). Injuries caused by exposure to cyanides are currently treated with. Scavengers such as human plasma-derived butyrylcholinesterase (HuBuChE), anti-epileptic drugs and neutralizing decontamination solutions such as 0.5% hypochloriate are also used to treat such injuries. Treatments for cyanide poisoning include hydroxocobalamin, sodium nitrite, and rhodanase. M291 resin kits are also currently used to treat topical injuries resulting from exposure to chemical warfare agents. Any of these agents can be combined with the TRPA1 antagonists described herein.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- The selected dosage level will depend upon a variety of factors including the activity of the particular compound disclosed herein employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- In general, a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. For example, the dose can be 1-50, 1-25, or 5-10 mg/kg.
- Compounds that antagonize TRPA1 function may be useful in the prophylaxis and treatment of any of the foregoing injuries, diseases, disorders, or conditions. In addition to in vitro assays of the activity of these compounds, their efficacy can be readily tested in one or more animal models. Compounds that may reduce pain or other undesirable symptoms in the animals can be readily tested by observing behavioral and/or physical characteristics of challenged animals in the presence versus the absence of the test compound(s) or procedure.
- Mouse Ear Edema Model. The mouse ear edema model provides a quantitative edema response as well as histopathological and biochemical endpoints as measurements of inflammation and tissue damage following exposure to the chemical warfare agent half mustard. The model is performed using CD-1 mice. Twenty-four hours following IP administration of test compound or vehicle, a solution of half mustard in organic solvent is applied to the inner surface of the right ear of each mouse. The left ear is not treated with half mustard and instead is maintained as a control. Animals are sacrificed at 24 hours, 72 hours, and 7 days post exposure to half mustard. The ear weights, draize scoring, and pathology are recorded at each time point. Half mustard injury in the mouse ear is measured by both edema response (fluid accumulation) and histopathological damage (necrosis, epidermal-dermal separation).
- In an alternate model, the test compound is administered therapeutically, e.g., immediately after, or one hour after exposure to half mustard. The models can also be performed using sulfur mustard or nitrogen mustard instead of half mustard.
- Guinea Pig Model for Nerve Agent Challenge. A Guinea pig model can be used to study the protective effects of the compounds against mortality induced by a nerve agent. The animals are pretreated with two IP doses of test compound, one IM dose of atropine, one IM dose of 2-PAM, or two IP doses of vehicle before challenge with 2×LD50 (s.c.) of a nerve agent. The animals are observed at 6 observation times post challenge. The number of animals in each group surviving 24 hours post challenge is then recorded.
- In an alternate model, the test compound, atropine, and 2-PAM are administered therapeutically, e.g., immediately after, or one hour after exposure to the nerve agent.
- The following examples are meant to be illustrative and are not meant to be limiting in any way.
- The assay depended on detection of the rise in intracellular Ca2+ concentration ([Ca2+]i) following channel activation in cells inducibly expressing the TRPA1 channel Ca2+ rise was quantified with the use of fluorescent Ca2+ indicators that were loaded into cells and thereafter indicated the [Ca2+]i. Ca2+ influx followed activation of the TRPA1 channel. Compounds inhibiting the [Ca2+]i rise were considered hits for further investigation.
- The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPA1 construct (specifically a construct encoding a TRPA1 protein with an amino acid sequence depicted in SEQ ID NO: 1 of WO 2007/073505) and screened by conventional calcium imaging to find clones with TRPA1 expression following stimulation with 1 μg/ml tetracycline. These cells were maintained in the growth medium recommended by the manufacturer supplemented with 100 μg/ml hygromycin to promote retention of the TRPA1 construct. After growing to near confluency, cells were plated at a density of ˜25,000 cells/well in 384 well CellBind plates (Corning) in the presence of 1 μg/ml tetracycline, and allowed to grow for 20-30 hrs. A nearly confluent monolayer resulted. Cells were then loaded with Ca2+ dye: Fura-2/AM or Fluo4/AM was added to the wells to a final concentration of 2 μM or 1 μM, respectively, and incubated for ˜60 min at room temperature. Supernatant was then removed from the cells by inverting plates with a sharp flick, and Hank's Balanced Salt Solution (HBSS; 0.185 g/l D-glucose, 0.9767 g/l MgSO4 (anhydrous), 0.4 g/l KCl, 0.06 g/l KH2PO4 (anhydrous), 0.35 g/l NaHCO3, 8.0 g/l NaCl, and 0.04788 g/l Na2HPO4 (anhydrous); pH 7.4) was then added to each well. Following recovery from loading, cells were assayed using the Hamamatsu FDSS 6000 system, which permitted illumination alternately at 340 nM and 380 nM for Fura-2 experiments, or at 485 nM for Fluo4 experiments. Frames were acquired at a rate of 0.2 Hz. For the screening assay, a diluted stock (at 50 μM) of compounds to be tested was added to each well for 2 minutes following the collection of a short (4 frame) baseline. AITC (allylisothiocyanate) was then added to each well, achieving a final concentration of 10 μM each compound and 7.5 μM AITC. Data were collected for at least 3 minutes following addition of AITC, and evaluated for the [Ca2+]i, which is proportional to the fluorescent intensity (for Fluo4) or the F340/F380 ratio (for Fura-2). Negative controls consisted of HEK293/TREx TRPA1 cells exposed to AITC, but no compound. Positive control cells were usually HEK293/TREx (“parental”) cells exposed to AITC but no compound, but sometimes normal HEK/293 TREx TRPA1 cells were also used, but not exposed to AITC or compound. These controls defined a screening window, and “hits” were defined as those compounds inhibiting the fluorescence response by at least 40%. IC50 values were determined for compounds defined as “hits.” The Fluo4 cell-based fluorescence assay was used to determine the intracellular Ca2+ concentration in the presence of varying drug concentration. To determine IC50 values, concentrations tested were 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, and 0.625 μM. Compounds were tested in triplicate at all concentrations. Standard software was used to fit IC50 curves.
- Additionally or alternatively, potency can be represented as % inhibition of a response in the presence (of a given concentration of compound) versus the absence of compound or in comparison to a control compound. For example, efficacy can be represented as % inhibition of ion flux in the presence versus the absence of compound.
- Patch clamp experiments permit the detection of currents through the TRPA1 channel in the cell line described above. The whole-cell configuration of the patch clamp technique was used to test the compounds described herein. In normal whole-cell patch clamp recordings, a glass electrode is brought into contact with a single cell and a high-resistance (gigaohm) seal is established with the cell membrane. The membrane is then ruptured to achieve the whole-cell configuration, permitting control of the voltage of the cell membrane and measurement of currents flowing across the membrane using the amplifier attached to the electrode and resulting in the replacement of cytoplasm with the pipette solution.
- HEK293/TREx TRPA1 cells were induced in the presence of 1 μg/ml tetracycline for 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separation) on glass coverslips for measurement. In some cases, cells were grown in low density overnight on glass coverslips. Potential blockers were tested for ability to block current in the continued presence of AITC.
- All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (19)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/466,187 US8318728B2 (en) | 2008-05-14 | 2009-05-14 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US13/655,316 US8710052B2 (en) | 2008-05-14 | 2012-10-18 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/198,050 US9260431B2 (en) | 2008-05-14 | 2014-03-05 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/989,030 US9980968B2 (en) | 2008-05-14 | 2016-01-06 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US15/964,653 US20180311248A1 (en) | 2008-05-14 | 2018-04-27 | Compounds and compositions for treating chemical warfare agent-induced injuries |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12768208P | 2008-05-14 | 2008-05-14 | |
US12766508P | 2008-05-14 | 2008-05-14 | |
US12766408P | 2008-05-14 | 2008-05-14 | |
US12779008P | 2008-05-14 | 2008-05-14 | |
US12766608P | 2008-05-14 | 2008-05-14 | |
US12772308P | 2008-05-14 | 2008-05-14 | |
US12778708P | 2008-05-14 | 2008-05-14 | |
US12/466,187 US8318728B2 (en) | 2008-05-14 | 2009-05-14 | Compounds and compositions for treating chemical warfare agent-induced injuries |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/655,316 Continuation US8710052B2 (en) | 2008-05-14 | 2012-10-18 | Compounds and compositions for treating chemical warfare agent-induced injuries |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120108613A1 true US20120108613A1 (en) | 2012-05-03 |
US8318728B2 US8318728B2 (en) | 2012-11-27 |
Family
ID=42074075
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/466,187 Active 2030-05-20 US8318728B2 (en) | 2008-05-14 | 2009-05-14 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US13/655,316 Active US8710052B2 (en) | 2008-05-14 | 2012-10-18 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/198,050 Active US9260431B2 (en) | 2008-05-14 | 2014-03-05 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/989,030 Active US9980968B2 (en) | 2008-05-14 | 2016-01-06 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US15/964,653 Abandoned US20180311248A1 (en) | 2008-05-14 | 2018-04-27 | Compounds and compositions for treating chemical warfare agent-induced injuries |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/655,316 Active US8710052B2 (en) | 2008-05-14 | 2012-10-18 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/198,050 Active US9260431B2 (en) | 2008-05-14 | 2014-03-05 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US14/989,030 Active US9980968B2 (en) | 2008-05-14 | 2016-01-06 | Compounds and compositions for treating chemical warfare agent-induced injuries |
US15/964,653 Abandoned US20180311248A1 (en) | 2008-05-14 | 2018-04-27 | Compounds and compositions for treating chemical warfare agent-induced injuries |
Country Status (2)
Country | Link |
---|---|
US (5) | US8318728B2 (en) |
WO (1) | WO2010039289A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9277748B2 (en) * | 2010-03-12 | 2016-03-08 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Agonist/antagonist compositions and methods of use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297494A (en) | 1978-08-09 | 1981-10-27 | Baxter Travenol Laboratories, Inc. | Xanthine tracers |
US4548939A (en) | 1984-10-01 | 1985-10-22 | Janssen Pharmaceutica N. V. | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
FR2608045B1 (en) | 1986-12-12 | 1990-03-02 | Chauvin Laboratoires | USE OF XANTHINE OXIDASE INHIBITORS, OXYGEN FREE RADIAL TRAPERS AND IRON CHELATORS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA |
HU198933B (en) | 1987-11-02 | 1989-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new xanthine derivatives and pharmaceutical compositions comprising same as active ingredient |
JP2843634B2 (en) | 1989-03-06 | 1999-01-06 | 協和醗酵工業株式会社 | Xanthine derivative |
GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US20030199693A1 (en) | 2000-07-28 | 2003-10-23 | Ing-Jun Chen | Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activies on PDE-5 phosphodiesterase |
EP1953162B9 (en) | 2001-02-24 | 2012-10-31 | Boehringer Ingelheim Pharma GmbH & Co. KG | Xanthin derivatives, their production and utilisation as medicine |
BR0302965A (en) | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Compound and method of treating a2b adenosine receptor mediated diseases |
EP1546377A4 (en) | 2002-02-28 | 2006-07-19 | Millennium Pharm Inc | Methods and compositions to treat pain and painful disorders using 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 or 13424 molecules |
BR0311760A (en) | 2002-06-12 | 2005-03-29 | Hoffmann La Roche | Compound, prodrug of a compound, process for preparing the compound, pharmaceutical compositions comprising the same, its use and method of treating type 2 diabetes |
US20050209243A1 (en) | 2002-09-27 | 2005-09-22 | Ing-Jun Chen | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
WO2007024680A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
AU2006327181A1 (en) | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
SI3184527T1 (en) | 2007-06-22 | 2020-03-31 | Eli Lilly And Company | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
US20110144137A1 (en) | 2008-05-07 | 2011-06-16 | Yale University | method for preventing or alleviating the noxious effects resulting from toxicant exposure |
WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009140519A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
US8362025B2 (en) | 2008-12-22 | 2013-01-29 | Hydra Biosciences, Inc. | Compositions useful for treating disorders related to TRPA1 |
-
2009
- 2009-05-14 WO PCT/US2009/043971 patent/WO2010039289A2/en active Application Filing
- 2009-05-14 US US12/466,187 patent/US8318728B2/en active Active
-
2012
- 2012-10-18 US US13/655,316 patent/US8710052B2/en active Active
-
2014
- 2014-03-05 US US14/198,050 patent/US9260431B2/en active Active
-
2016
- 2016-01-06 US US14/989,030 patent/US9980968B2/en active Active
-
2018
- 2018-04-27 US US15/964,653 patent/US20180311248A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
Cassillas et al, J. Appl. Toxicol. 20, S145-S151 (2000). * |
Also Published As
Publication number | Publication date |
---|---|
US9980968B2 (en) | 2018-05-29 |
WO2010039289A3 (en) | 2010-07-22 |
US20160354379A1 (en) | 2016-12-08 |
US20130165454A1 (en) | 2013-06-27 |
US8710052B2 (en) | 2014-04-29 |
US8318728B2 (en) | 2012-11-27 |
US9260431B2 (en) | 2016-02-16 |
WO2010039289A2 (en) | 2010-04-08 |
US20180311248A1 (en) | 2018-11-01 |
US20140303192A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10703754B2 (en) | Compounds and compositions for treating chemical warfare agent-induced injuries | |
US20130165427A1 (en) | Compounds and compositions for treating chemical warfare agent-induced injuries | |
US9895356B2 (en) | Methods and compositions for treating anxiety | |
AU2018200591B2 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
RU2478387C2 (en) | IMIDASOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | |
AU2009247251B2 (en) | Pharmaceutical preparation comprising DPP-IV inhibitor and other diabetes therapeutic agent in concomitant or combined form | |
US20120046305A1 (en) | Methods and compositions for treating respiratory disorders | |
US20040242673A1 (en) | Heterocyclic compounds and uses thereof | |
CA2659770C (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
EP2258372A1 (en) | A2A antagonists for use in the treatment of motor disorders | |
US6348470B1 (en) | Antitussive compositions | |
WO2010132838A1 (en) | Compounds useful for treating disorders related to trpa1 | |
US9980968B2 (en) | Compounds and compositions for treating chemical warfare agent-induced injuries | |
KR20060004959A (en) | Method of improved diuresis in individuals with impaired renal function | |
US8952023B1 (en) | Compounds useful for treating injuries from warfare agents | |
EP3270923B1 (en) | Therapeutic agent for frontal lobe dysfunction | |
EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia | |
WO2024076999A2 (en) | Gabaa receptor modulators and uses thereof | |
EA012033B1 (en) | Use of desoxypeganine for the treatment of schizophrenic psychoses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HYDRA BIOSCIENCES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHONG, JAYHONG A.;REEL/FRAME:022926/0943 Effective date: 20090617 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |